Ž©—R‰¿Ši@Top ‘Ðˆê—— Œ¤‹†ŠJ”­ƒ}ƒlƒWƒƒ“ƒg ‰»Šw ƒGƒŒƒNƒgƒƒjƒNƒX ˆã@@–ò HOME
 
 

”sŒŒÇ@‘Ð
No.1726

 
gŽ¡Œ±Ž¸”shgŠJ”­’†Ž~h......Ž¡—Â̌»óEŽ–—á‚𓥂܂¦‚½¡Œã‚ÌŠJ”­‚ɖ𗧂I

”sŒŒÇ‚̐f’f/Ž¡—Â̎Àó‚Æ •a‘ԁEƒƒJƒjƒYƒ€‚ð‚Ó‚Ü‚¦‚½ŠJ”­í—ª

- Ž¡—ÖòAf’f–òEŽŽ–òAˆã—Ë@ŠíE‘•’u -

”­@Š§@‚Q‚O‚P‚R”N@‚WŒŽ‚R‚O“ú@@‘́@ÙF‚`‚S”»@‚U‚Q‚R•Å@@’è@‰¿F95,000iÅ”²j

@@ Ž¡Œ±‚Å‚Ì—LŒø«‚ð‚ǂ̂悤‚É•]‰¿‚·‚é‚©H
@@ ”ºÇóE‡•¹Ç‚Ö‚ÌŽ¡—ÂƗLŒø«•]‰¿—á
@@ ƒvƒƒJƒ‹ƒVƒgƒjƒ“AŒŒ‰t”|—{AŒ´ˆö‹Û‚̐v‘¬“¯’èAŠ´“xE“ÁˆÙ“x ...... ŒŸ¸Ef’f‚ÌŒ»ó‚́H


¡@–{‘‚̃|ƒCƒ“ƒg

 ƒƒJƒjƒYƒ€‚ÆŠî‘bŒ¤‹†‚̐i‚ß•û
@@- ‰ŠÇ”½‰žA‹ÃŒÅ”½‰žAAƒƒJƒjƒYƒ€Œ¤‹†‚Ì“®Œü‚́H
@@- ŠeŽíƒ‚ƒfƒ‹“®•¨‚Ì“Á’¥‚Æ•a‘ԁA–òŒø•]‰¿
@@- –ò—ŠwA•a—ŠwA–ƉuŠwA»ÜŠw‚ÌŠeŽ‹“_‚©‚猩‚½¡Œã‚ÌŒ¤‹†ŠJ”­

 ƒoƒCƒIƒ}[ƒJ[‚Ì’TõEŠJ”­
@@- ƒ}[ƒJ[‚Ì’Tõ‚ƗՏ°‰ž—p‚Ì“®Œü
@@- ”­ÇƒŠƒXƒNAŽ¡—ЬÑ‚Ì—\‘ª‚ւ̉ž—p

 f’f–òE‹Zp‚ÌŠJ”­‚ƍ¡Œã‚̕ω»—\‘ª
@@- —Տ°Œ»ê‚Å‚ÌŒŸ¸AŒŒ‰t”|—{Af’f‚ÌŒ»ó‚́H
@@- f’fEŽ¡—Â̗¬‚ê‚Í‚Ç‚¤•Ï‰»‚·‚éH

ŒŒ‰tò‰»—Ö@E•a‘Ôƒ‚ƒjƒ^ƒŠƒ“ƒO
@@- ŒŒ‰tò‰»—Ö@‚Ì—˜_‚ÆŒ»ó
@@- ƒGƒ“ƒhƒgƒLƒVƒ“‚Ì‹z’…Œø‰Ê‚Ɛ«”\‚Ì•]‰¿—á^—Տ°ŽŽŒ±E»•i‰»‚ÌŽ–—á
@@- ŒÄ‹zES”EŒŒ‰tE‘ãŽÓ‚̃‚ƒjƒ^ƒŠƒ“ƒO‹Zp‚Æ‘•’uŠJ”­

¡Œã‚̐f’fEŽ¡—Â̕ω»—\‘ª‚ÆŽg—p‚³‚ê‚È‚­‚È‚é‚Å‚ ‚낤–òÜE»•i

Ž¡Œ±^—Տ°ŽŽŒ±‚ÌŽÀ‘H‚Æ—LŒø«EˆÀ‘S«‚Ì•]‰¿
@@- —Տ°‚Å‚Ì“Š—^—ʁA—p–@‚̐ݒè
@@- ”팱ŽÒ‘I’èAÇ—áƒGƒ“ƒgƒŠ[
@@- Ž¡Œ±ƒfƒUƒCƒ“‚ƃGƒ“ƒhƒ|ƒCƒ“ƒgÝ’è
@@- Ž¡Œ±‚̕⏞‚Ɣ͈́E‹àŠzÝ’è
@@- —LŠQŽ–Û‚ÆŽs”̌㒲¸—á

Žsê—\‘ª‚ÆŽ–‹Æí—ª
@@- Š³ŽÒ”—\‘ª‚ÆŽsê•ªÍE”„ã—\‘ª‚̃Aƒvƒ[ƒ`–@‚́H
@@- ”ï—pŒø‰Ê‚ƈã—ÃŒoÏ«‚Ì•ªÍ—á
@@- “Á‹–í—ªEƒ‰ƒCƒZƒ“ƒXŽž‚Ì—¯ˆÓ“_

”ºÇóE‡•¹Ç‚ÆŽ¡—ÃŒø‰Ê‚Ì—LŒø«•]‰¿
@@- DICA”]áŠQA‘–Œ‰ŠAS“à–Œ‰ŠAtáŠQAŠÌáŠQA”xáŠQAŠÖß‰ŠA
@@@@@‚»‚ꂼ‚ê‚ÌŽ¡—Â̌»ó‚ƗՏ°•]‰¿‚Ƃ́H

Ž¡—ÃŒ»ê‚Ì‹ï‘Ì“I‚ȃj[ƒY‚Æ‹‚߂鎡—Öò
@@- Šef—ÉȂɂ¨‚¯‚é”sŒŒÇŽ¡—Â̌»ó‚ƃAƒ“ƒƒbƒgƒj[ƒY
@@- ‚ª‚ñA‰ŠÇ«Ž¾Š³A“œ”A•aAŠ´õÇAˆÚAˆã—Âɂ¨‚¯‚é•a‘ԁEŽ¡—ÂƃAƒ“ƒƒbƒgƒj[ƒY

¡@Ž·•MŽÒiŒhÌ—ªj
–kŠC“¹‘åŠw•a‰@ ‘ì•ôŽi VŠƒ‘åŠwˆãŽ•Šw‘‡•a‰@ ÔàVG•½
–¼ŒÃ‰®Žs—§‘åŠw‘åŠw‰@ ‰Á“¡ä“T “¡“c•ÛŒ’‰q¶‘åŠw Îì´m
“Œ–k–ò‰È‘åŠw âŒûC•½ ‘åã•{òB‹~–½‹~‹}ƒZƒ“ƒ^[ ’†“cF–¾
“Œ–k–ò‰È‘åŠw ‰i“c´ ‘åã•{òB‹~–½‹~‹}ƒZƒ“ƒ^[ ¼‰ª“N–ç
‰ªŽR‘åŠw‘åŠw‰@ ”‘q~Æ ŒN’Ã’†‰›•a‰@ –k‘ºLÆ
‰ªŽR‘åŠw‘åŠw‰@ ¼ìº”Ž ˜a‰ÌŽRŒ§—§ˆã‰È‘åŠw ì•›—F
“ŒƒŒ(Š”) “‡“cŒO ˜a‰ÌŽRŒ§—§ˆã‰È‘åŠw ‹{–{‹±•º
“Œ‹žˆã‰È‘åŠw”ª‰¤Žqˆã—ÃZƒ“ƒ^[ ’r“cŽõº ‘å“ú–{Z—F»–ò(Š”) Žá‘º—F‘¾˜Y
“ŒƒŒ(Š”) ŽO˜aŒhŽj ‘å“ú–{Z—F»–ò(Š”) ²“¡‹M”V
‹ãB‘åŠw ”ÑŽR˜aO •Ÿ‰ª‘åŠw•a‰@ ‰ª–{ˆÉ“ÞŽq
“Þ—ÇŒ§—§ˆã‰È‘åŠw ŒÃ¼–ž •Ÿ‰ª‘åŠw ‘å‹v•Û‹v”üŽq
“Þ—ÇŒ§—§ˆã‰È‘åŠw ‰F–쌒Ži º˜a‘åˆãŠw•”i‚i•‚sŽ¡Œ±mj ’ҏƒˆê˜Y
(Š”)‘å’ː»–òHê ¼‘º‰v_ ŠOŽ‘ŒnŠé‹Æ ŠJ”­’S“–ŽÒ
(Š”)‘å’ː»–òHê “à“¡^ô ƒj[ƒ‹ƒZƒ“(Œ³“ú–{ƒC[ƒ‰ƒCƒŠƒŠ[) ‘“cˆê˜Y
(Š”)‘å’ː»–òHê Œb”üL’j ƒj[ƒ‹ƒZƒ“ ¬]‰À—mŽq
“Œ‹ž‘åŠw¶ŽY‹ZpŒ¤‹†Š –öˆäGŒ³ ƒj[ƒ‹ƒZƒ“ ¬”¦—R‹IŽq
“Œ‹ž‘åŠw¶ŽY‹ZpŒ¤‹†Š ç—tŽu•ä Nielsen JulieClemens
Œcœä‹`m‘åŠw ²X–؏~ˆê ƒNƒŒƒRƒ“E ˆäãKŒb
’é‘åŠw ’|‰ºŒ[‘  @ ƒŠƒT[ƒ`ƒAƒ“ƒhƒRƒ“ƒTƒ‹ƒeƒBƒ“ƒO(Š”)  
’é‘åŠw ‰ªèËŽq “ú–{‹Zp–fˆÕ(Š”) ‹àŽq•qK
ˆ®‰»¬ƒtƒ@[ƒ}(Š”) –{“c„ˆê ŽOŽ}‘Û“Á‹–Ž––±Š X“ˆ³Ž÷
—鎭ˆã—ÉȊw‘åŠw —é–؍GŽ¡ ‰®‘ã•Ù—ŽmŽ––±Š(Œ³ƒG[ƒUƒC) ‰®‘㏇Ž¡˜Y
•xŽR‘åŠw‘åŠw‰@ “cŒû‹v”üŽq ‹ž“s‘æˆêÔ\Žš•a‰@ “V’J•¶¹
•xŽR‘åŠw‘åŠw‰@ •ž•”—Tˆê ŠÖ¼ˆã‰È‘åŠw•‘®–‡•û•a‰@ ¼Œ›ˆê˜Y
“¡“c•ÛŒ’‰q¶‘åŠw ’犰 NTT“Œ“ú–{ŠÖ“Œ•a‰@ ŽR–{•Žj
’}”g‘åŠw ¬“c‚¿‚®‚³ ‹Ë¶Œú¶‘‡•a‰@ ŒK“‡M
’}”g‘åŠw a’J² ‹Ë¶Œú¶‘‡•a‰@ ŠÛ“c‰h
‹ž“s–ò‰È‘åŠw ŸŒ©‰p³ º˜a‘åŠw•a‰@ •Ÿ“cŒ«ˆê˜Y
‹ž“s–ò‰È‘åŠw ŽR–{¹ º˜a‘åŠw•a‰@ ŽO‘îNŽj
ŠâŽèˆã‰È‘åŠw ˆî“c·–ç ²‰ê‘åŠw ã–{—Yˆê˜Y
–h‰qˆã‰È‘åŠwZ ¬–쑏 ŒQ”n‘åŠwˆãŠw•”•‘®•a‰@ –åˆä—YŽi
˜aŒõƒ–òH‹Æ(Š”) ’†”öFˆê •Ÿ“‡Œ§—§ˆã‰È‘åŠw ×–îŒõ—º
‚’mˆã—ÃZƒ“ƒ^[ •ŸˆäN—Y é‹Êˆã‰È‘åŠw‘Ûˆã—ÃZƒ“ƒ^[ ‹{—¢–¾Žq
ŠâŽèˆã‰È‘åŠw ‰““¡dŒú ‹ž“s‘æ“ñÔ\Žš•a‰@ žwŠ_‘
•Ÿ‰ª‘åŠw Î‘qG‹± ‹ž“s‘åŠw ¬’rŒO
Š ’J–L“c‘‡•a‰@ ŽO‰Y­’¼ Ž ‰êˆã‰È‘åŠw Ô–x_–ç
“Œ‹ž‘åŠwæ’[‰ÈŠw‹ZpŒ¤‹†ƒZƒ“ƒ^[ •lŒE—²—Y Ž ‰êˆã‰È‘åŠw ’‡¬K
“Œ‹ž‘åŠwæ’[‰ÈŠw‹ZpŒ¤‹†ƒZƒ“ƒ^[ ‘¾ŠúŒ’“ñ Ž ‰êˆã‰È‘åŠw ‰–Œ©®—ç
“Œ‹žˆã‰È‘åŠw”ª‰¤Žqˆã—ÃZƒ“ƒ^[ óŠC—²Ži Ž ‰êˆã‰È‘åŠw ‘ºãkˆê˜Y
ŽOd‘åŠw‘åŠw‰@ ‰ª–{‹Ms Ž ‰êˆã‰È‘åŠw ´…’qŽ¡
“Þ—ÇŒ§—§ˆã‰È‘åŠw ¼”öŒ’Ž¡ Ž ‰êˆã‰È‘åŠw ’J“O
“Œ‹ž–ò‰È‘åŠw •½–ìr•F ‘q•~¬l•aƒZƒ“ƒ^[ ŽODM–ç
MB‘åŠw –{“cFs ‹ž“s•{—§ˆã‰È‘åŠw ‹´–{Œå
MB‘åŠw ›–ìŒõr –¼ŒÃ‰®‘åŠwˆãŠw•”•‘®•a‰@ ‰œ‘º‹M—T
MB‘åŠw ìèŒ’Ž¡ ‹{è‘åŠw ˜@’rŒå
‘åã‘åŠwˆãŠw•”•‘®•a‰@ ŠÖ‰ë•¶ ‹{è‘åŠw ‘剀–F”Í
‘åã‘åŠwˆãŠw•”•‘®•a‰@ ’©–ì˜a“T ‹{è‘åŠw ‰º“c˜aÆ
“ú–{ˆã‰È‘åŠw•t‘®•a‰@ ŽÄ“c‘׎j º˜a‘åŠw“¡‚ª‹u•a‰@ “ï”g‹`’m
ƒVƒXƒƒbƒNƒXEƒrƒIƒƒŠƒ…[(Š”) ŠÖŒûKŒb º˜a‘åŠw“¡‚ª‹u•a‰@ ¼Œ´–Ґl
“ú–{ƒxƒNƒgƒ“EƒfƒBƒbƒLƒ“ƒ\ƒ“(Š”) ¬—шè•v ‹ž“s–¯ˆã˜A’†‰›•a‰@ ˆäã‰êŒ³
(Š”)ƒvƒƒbƒvƒW[ƒ“ ìŒû—³“ñ ‹ß‹E’†‰›‹¹•”Ž¾Š³ƒZƒ“ƒ^[ ‘qŒ´—D
•xŽR‘åŠw•‘®•a‰@ mˆäŒ©‰pŽ÷ ìèˆã‰È‘åŠw ŒÃì”ŽŽj
ƒVƒ~ƒbƒN(Š”) “‡“c³•v “ú–{‘åŠw ŽR’†–푾˜Y
ƒV[ƒƒ“ƒXƒwƒ‹ƒXƒPƒAE ‰¬Œ´‹M—T “ú–{‘åŠw ûü‹´Œå
@@@@ƒ_ƒCƒAƒOƒmƒXƒeƒBƒNƒX(Š”)   •ºŒÉˆã‰È‘åŠw “ªŽi—Y‰î
‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@ Y’J’¼l •ºŒÉˆã‰È‘åŠw ŠÝ–{—T[
’·è‘åŠw•a‰@ –öŒ´Ž‹I •ºŒÉˆã‰È‘åŠw ‰Yo‰ë—T
’·èŽs—§Žs–¯•a‰@ ã•½Œ› ‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@ Œõ‰iCˆê
Œà‹¤Ï•a‰@ r’Jç“o”ü Œö‰và’c–@l‚ª‚ñŒ¤‹†‰ï ‚ª‚ñŒ¤—L–¾•a‰@ ˆäã‘å
ç—t‘åŠw‘åŠw‰@ •ž•”Œ›K ‘—§•a‰@‹@\“ªŽR•a‰@ X‰ëG
ç—t‘åŠw‘åŠw‰@ D“c¬l ’¹Žæ‘åŠw ²“¡½–ç
“ŒƒŒEƒƒfƒBƒJƒ‹(Š”) ¬˜H‹vŒh ’¹Žæ‘åŠw “‡“c@º
“¡“c•ÛŒ’‰q¶‘åŠw Œ´‰ÃF ’¹Žæ‘åŠwˆãŠw•”•‘®•a‰@‚ª‚ñƒZƒ“ƒ^[ ‹IìƒŽO
“¡“c•ÛŒ’‰q¶‘åŠw ¼“cC Œö‰và’c–@l‚ª‚ñŒ¤‹†‰ï ‚ª‚ñŒ¤—L–¾•a‰@ ÆˆäNm
ˆ®‰»¬(Š”) ¼‘º—²—Y VŠƒŒ§—§‚ª‚ñƒZƒ“ƒ^[VŠƒ•a‰@ ‚‹´‰p–¾
¹ƒ}ƒŠƒAƒ“ƒiˆã‰È‘åŠw M‰ª—S•F ŒF–{‘åŠw Žwh–rŽq
Šò•Œ‘åŠw@ ‰¡“cN¬ ŒF–{‘åŠw ŽR–{–L
Šò•Œ‘åŠw@ ‰Í‘º—mŽq ŒF–{‘åŠw Šâ£OŒh
Šò•Œ‘åŠwˆãŠw•”•‘®•a‰@ ”’ˆä–M”Ž ‡“V“°‘åŠw ‹v––Lˆê
Šò•Œ‘åŠwˆãŠw•”•‘®•a‰@ ¼ŠÛ’¼Ž÷ ‡“V“°‘åŠw –x]d˜Y
ŽD–yˆã‰È‘åŠw ¡ò‹Ï ‚ª‚ñEŠ´õÇƒZƒ“ƒ^[“s—§‹îž•a‰@ ‚‹´GŽ¡
ŽD–yˆã‰È‘åŠw ¡“cDŽ÷ _ŒË‘åŠwˆãŠw•”•‘®•a‰@ ˆüŽR‹ˆê
ŽD–yˆã‰È‘åŠw ’F”Žb •Ÿ“‡Œ§—§ˆã‰È‘åŠw ‘åÎŒ›ˆê
ŽD–yˆã‰È‘åŠw çŒ´L–ç •Ÿ“‡Œ§—§ˆã‰È‘åŠw ÀèL–@
“ú–{ˆã‰È‘åŠw•‘ ¬™•a‰@ ‘ºàVP’j •Ÿ“‡Œ§—§ˆã‰È‘åŠw ®–ìœÄˆê
“ú–{ˆã‰È‘åŠw•‘ ¬™•a‰@ ‘å’Ë’q”V Œb¶‰ïã”’ª•a‰@ ‘å–î’¼Žq
“ú–{ˆã‰È‘åŠw•‘ ¬™•a‰@ ‘å–ì‘å (“Æ)‘—§•a‰@‹@\ ‚܂‚à‚ƈã—ÃZƒ“ƒ^[ ‘q“cŒ¤Ž™
“ú–{ˆã‰È‘åŠw•‘ ¬™•a‰@ Žðˆäs’¼ (“Æ)‘—§•a‰@‹@\ ‚܂‚à‚ƈã—ÃZƒ“ƒ^[ Â–Ø—YŽŸ
“ú–{ˆã‰È‘åŠw•‘ ¬™•a‰@ ˆé–ì—Fº ‹à‘ò‘åŠwˆã–ò•ÛŒ’Œ¤‹†ˆæˆãŠwŒn Žðˆä‰À•v
“ú–{ˆã‰È‘åŠw•‘ ¬™•a‰@ –叼–L ‹à‘ò‘åŠwˆã–ò•ÛŒ’Œ¤‹†ˆæˆãŠwŒn ‹àŽqŽüˆê
‘åã‘åŠwˆãŠw•”•‘®•a‰@ ’†ì—YŒö ‘啪‘åŠwˆãŠw•”•‘®•a‰@ –å“c~ˆê
àՋ¦ˆã‰È‘åŠw‰z’J•a‰@ b“c—º ‘啪‘åŠwˆãŠw•”•‘®•a‰@ •½¼˜aŽj
àՋ¦ˆã‰È‘åŠw‰z’J•a‰@ ’|“c“O˜N ‘啪‘åŠwˆãŠw•”•‘®•a‰@ …ãŠG—
“¯ŽuŽÐ—Žq‘åŠw ¼Œ³‰Á“Þ ‰¡•lŽs—§‘åŠw•‘®•a‰@ •“c˜a‰i
“¯ŽuŽÐ—Žq‘åŠw X“c–M•F ‰¡•lŽs—§‘åŠw•‘®•a‰@ ‰““¡Ši
“Œ‹žŽœŒb‰ïˆã‰È‘åŠw –x–ì“N–ç ì‘åŠw ‘c•ƒ]—
Ž ‰êˆã‰È‘åŠwˆãŠw•”•‘®•a‰@ â»Žq —®‹…‘åŠw‘åŠw‰@ —FŠñ‹Bº
_ŒË‘åŠw‘åŠw‰@ rì‘nˆê —®‹…‘åŠwˆãŠw•”•‘®•a‰@ ’‡’n²˜aŽq
“Œ‹ž—Žqˆã‰È‘åŠw“Œˆã—ÃZƒ“ƒ^[ ˆé’J‰h“ñ @ @
¡@–ځ@@ŽŸ 
 

@@@@y‘æ‚P•”z@”sŒŒÇ‚̃ƒJƒjƒYƒ€‚ÆŠî‘bŒ¤‹†‚̐i‚ß•û

@@@@y‘æ‚Q•”z@”sŒŒÇ‚̃oƒCƒIƒ}[ƒJ[‚ÌŠJ”­

@@@@y‘æ‚R•”z@”sŒŒÇ‚ÌŒŸ¸‚Ɛf’f–òEf’f‹Zp‚ÌŠJ”­

@@@@y‘æ‚S•”z@ŒŒ‰tò‰»—Ö@A•a‘Ôƒ‚ƒjƒ^ƒŠƒ“ƒO‚ƈã—Íޗ¿E‹@ŠíŠJ”­

@@@@y‘æ‚T•”z@”sŒŒÇ‚É‚¨‚¯‚é–òÜŠJ”­E—Տ°ŽŽŒ±‚ÌŽÀ‘H

@@@@y‘æ‚U•”z@”sŒŒÇŽ¡—Öò‚ÌŽsê—\‘ª‚ÆŽ–‹Æí—ª

@@@@y‘æ‚V•”z@”sŒŒÇ—R—ˆ‚ÌŽ¾Š³‚ÌŽ¡—ÂƗLŒø«•]‰¿

@@@@y‘æ‚W•”z@—Տ°Œ»ê‚Ì”sŒŒÇŽ¡—Ẫj[ƒY‚ÆŒ¤‹†ŠJ”­

Ÿ ‘æ‚PÍF”sŒŒÇ‚̃ƒJƒjƒYƒ€‚ÆŠî‘bŒ¤‹†‚̐i‚ß•û @ 
‘æ‚PßF ”sŒŒÇ‚Ì•a‘ԂƃƒJƒjƒYƒ€
@1D”sŒŒÇ‚Ì’è‹`
@2D”sŒŒÇ‚Ɛ¶‘Ì”½‰ž
@@2.1 –Ɖu‰ŠÇ”½‰ž
@@@2.1.1 H×–Eiphagocytej
@@@2.1.2 •â‘ÌŒn
@@@2.1.3 ƒpƒ^[ƒ“”FŽ¯Žó—e‘́ipattern recognition receptor, PRRj
@@@2.1.4 PRR‚©‚ç‚̏î•ñ“`’B
@@2.2 _Œo“à•ª”唽‰ž
@@@2.2.1 Š´õ«NP‚ÌŠ´’m
@@@2.2.2 _Œo“à•ª”唽‰ž
@@2.3 ‹ÃŒÅü—n”½‰ž

‘æ‚QßF “®•¨ƒ‚ƒfƒ‹‚̍쐬‚Æ•a‘ԁE–òŒø‚Ì•]‰¿

@m‚Pn• –Œ‰Šƒ‚ƒfƒ‹‚Ì“Á’¥Eì¬‚Æ•]‰¿
@@1D‘¼‚Ìsepsisƒ‚ƒfƒ‹‚Æ‚Ì”äŠr
@@@1.1 LPS“Š—^ƒ‚ƒfƒ‹
@@@1.2 ¶‹Û“Š—^ƒ‚ƒfƒ‹
@@2D• –Œ‰Šƒ‚ƒfƒ‹
@@@2.1 ’è—Ê“I• o“àŠ´õ‘ƒì¬ƒ‚ƒfƒ‹
@@@2.2 •³•Ö«• –Œ‰Šƒ‚ƒfƒ‹
@@@2.3 Á‰»ŠÇúEƒ‚ƒfƒ‹
@@@@2.3.1 “®•¨‚ɉÁ‚¦‚éŽè‹Z
@@@@@- Œ‹ãF‚·‚é–Ó’°‚Ì’·‚³
@@@@@- • o“à‚ɘR‚ꂾ‚·×‹Û‚Ì—Ê
@@@@@- ³’†ØŠJ‚Ì‘å‚«‚³A”畆A‹Ø‘w‚̏
@@@@@- Žg—p‚·‚é–ƒŒ–ò
@@@@@- Žèp‚ðs‚¤“ú—߂⎞ŠÔ‘Ñ
@@@@@- «•ÊA”N—îA“®•¨Ží
@@@@@- hŽå”½‰ž‚Ì‘½—l«
@@@@@- —A‰t‚âR¶Ü“Š—^“™‚̕⏕—Ö@‚Ì—L–³
@@3D¡Œã‚̉ۑè

@m‚QnƒGƒ“ƒhƒgƒLƒVƒ“ŒŒŸ÷ƒ‚ƒfƒ‹
@ ƒ‚P„ ƒGƒ“ƒhƒgƒLƒVƒ“Š´Žó«ƒRƒ“ƒgƒ[ƒ‹ƒ‚ƒfƒ‹‚̍쐬‚Æ•a‘ԁE–òŒø•]‰¿
@@@@1DƒGƒ“ƒhƒgƒLƒVƒ“‚ɑ΂·‚éŠeŽí“®•¨‚ÌŠ´Žó«‚̍·
@@@@2DƒGƒ“ƒhƒgƒLƒVƒ“Š´Žó«‚̘´i
@@@@@2.1 Š´õ‚É”º‚¤Š´Žó«‚̏㏸
@@@@@2.2 ƒJƒ‰ƒM[ƒiƒ“Š´Žó«
@@@@@2.3 •›t“Eo
@@@@3D–Ô“àŒn‹@”\‚̏Cü‚ƃGƒ“ƒhƒgƒLƒVƒ“Š´Žó«‚̘´i

@ ƒ‚Q„ “àˆö«”sŒŒÇ«ƒVƒ‡ƒbƒNƒ‚ƒfƒ‹‚̍쐬‚Æ•a‘ԁE–òŒø•]‰¿
@@@@1DIn vivo ‚Å‚Ì“àˆö«”sŒŒÇƒ‚ƒfƒ‹
@@@@@1.1 TNF-ƒ¿‚ÆD-ƒKƒ‰ƒNƒgƒTƒ~ƒ“(GalN)
@@@@@1.2 GalN•‰‰×‚É‚æ‚éTNFƒ¿Š´Žó«‘‘å‚Æ
@@@@@@@@@ ŠÌŽ¾Š³‚É‚¨‚¯‚é’°ŠÇ—R—ˆ‚Ì“àˆö«ƒGƒ“ƒhƒgƒLƒVƒ“‚ÌŠÖ—^
@@@@@1.3 TNF-ƒ¿‚Æ“àˆö«ƒGƒ“ƒhƒgƒLƒVƒ“‚Ì‘Šæì—p
@@@@2DIn vitro ‚ł̊̍זEŒn‚Ì”sŒŒÇƒ‚ƒfƒ‹‚̍\’z
@@@@@2.1 HepG2 ×–E‚ð—p‚¢‚½Ž_‰»ƒXƒgƒŒƒXƒ‚ƒfƒ‹‚Ɗ̏áŠQ«•]‰¿Œn‚̍\’z
@@@@3D¡Œã‚Ì”sŒŒÇŽ¡—ÖòŠJ”­‚Ì“W–]

@m‚Rnƒ‚ƒfƒ‹Ží‚Ì‘I‘ðEì¬‚Æ•]‰¿—á
@ ƒ‚P„ –Ó’°Œ‹ãFúEƒ‚ƒfƒ‹‚̍쐬‚Æ•]‰¿—á
@@@@1DCLP‚Ì•û–@
@@@@@1.1 —pˆÓ‚·‚é‚à‚Ì
@@@@@1.2 ŽèpŽè‹Z
@@@@2D•]‰¿•û–@
@@@@@2.1 ¶‘¶—¦
@@@@@2.2 ×–E”
@@@@@2.3 ŒŒ‰t”|—{A• …”|—{
@@@@@2.4 ƒTƒCƒgƒJƒCƒ“ŽY¶—Ê
@@@@@2.5 ‚»‚Ì‘¼

@ ƒ‚Q„ ƒuƒ^”sŒŒÇƒ‚ƒfƒ‹‚̍쐬‚Æ•]‰¿
@@@@@@@`TSST-1‚¨‚æ‚ÑLPS“Š—^‚É‚æ‚é”sŒŒÇ«‹}«”xáŠQƒ‚ƒfƒ‹‚̍쐻‚Æ
@@@@@@@@@@@@@ ƒX[ƒp[RŒ´‚¨‚æ‚уTƒCƒgƒJƒCƒ“œ‹ŽƒJƒ‰ƒ€‚Ì—LŒø«•]‰¿`
@@@@1D”sŒŒÇ«‹}«”xáŠQƒ‚ƒfƒ‹‚̍쐻
@@@@@1.1 ƒ‚ƒfƒ‹“®•¨‚̐݌v
@@@@@1.2 ƒuƒ^‚ð—p‚¢‚½TSST-1‚¨‚æ‚ÑLPS‚É‚æ‚é”sŒŒÇ«‹}«”xáŠQƒ‚ƒfƒ‹‚̍쐻
@@@@@@1.2.1 “®•¨
@@@@@@1.2.2 TSST-1‚¨‚æ‚ÑLPS‚Ì“Š—^•û–@
@@@@@@1.2.3 ŠO‰È“Iˆ’u
@@@@2D”sŒŒÇ«‹}«”xáŠQƒ‚ƒfƒ‹‚ð—p‚¢‚½—LŒø«‚Ì•]‰¿
@@@@@2.1 ƒX[ƒp[RŒ´‚¨‚æ‚уTƒCƒgƒJƒCƒ“œ‹ŽƒJƒ‰ƒ€
@@@@@2.2 ƒX[ƒp[RŒ´‚¨‚æ‚уTƒCƒgƒJƒCƒ“œ‹ŽƒJƒ‰ƒ€‚Ì‹z’…“Á«
@@@@@2.3 ƒX[ƒp[RŒ´‚¨‚æ‚уTƒCƒgƒJƒCƒ“œ‹ŽƒJƒ‰ƒ€‚ð—p‚¢‚½‘ÌŠOzŠÂŽ¡—Õû–@
@@@@@2.4 ”sŒŒÇ«‹}«”xáŠQ‚ÌŽ¡—ÃŒø‰Ê

@ ƒ‚R„ ƒJƒCƒR”sŒŒÇƒ‚ƒfƒ‹‚̍쐬‚Æ•]‰¿
@@@@1. ƒJƒCƒR‚Ì“Á’¥
@@@@@1.1 ‘å—ÊŽ”ˆç@
@@@@@1.2 ¶•¨Šw“I“Á’¥
@@@@@1.3 ƒJƒCƒR‚ð—p‚¢‚½Œ¤‹†‚̍ð¡
@@@@2. —Δ^‹Û•ÏˆÙŠ”‚̃JƒCƒR‚ɑ΂·‚é•aŒ´«
@@@@@2.1 ƒGƒLƒ\ƒgƒLƒVƒ“A
@@@@@2.2 ƒX[ƒp[ƒIƒLƒVƒhƒWƒXƒ€ƒ^[ƒ[
@@@@@2.3 ƒsƒIƒVƒAƒjƒ“
@@@@@2.4 ‚Ù“û—ނƃJƒCƒR‚É‚¨‚¯‚é—Δ^‹Û•aŒ´—͈öŽq‚Ì‹¤’Ê“_C‘Šˆá“_
@@@@3. ŽÀŒ±Žè–@
@@@@@3.1 ƒJƒCƒR‚ÌŽ”ˆç
@@@@@3.2 ÚŽíŒ¹‚Ì’²»‚¨‚æ‚ѐڎí
@@@@@3.3 ŽÀŒ±Œã
@@@@4. ƒJƒCƒRClHŽ”—¿‚Ì“üŽèæ
@@@@@4.1 Ž\Ží
@@@@@4.2 lHŽ”—¿

@ ƒ‚S„ ƒJƒ“ƒWƒ_”sŒŒÇƒ‚ƒfƒ‹‚̍쐬‚Æ•]‰¿—á
@@@@1DƒJƒ“ƒWƒ_‚ð’°“àíÝ‹Û‚Æ‚·‚é•û–@
@@@@@1.1 ƒ}ƒEƒX‚Ì’°“à×‹Û
@@@@@1.2 ƒJƒ“ƒWƒ_‚Ì’°“àíÝ‹Û‰»
@@@@2DƒJƒ“ƒWƒ_”sŒŒÇƒ‚ƒfƒ‹‚̍쐬
@@@@@2.1 ƒJƒ“ƒWƒ_”sŒŒÇƒ‚ƒfƒ‹ì¬‚̃vƒƒgƒR[ƒ‹
@@@@@2.2 ƒJƒ“ƒWƒ_”sŒŒÇƒ‚ƒfƒ‹‚ÌŒŸØ
@@@@3DƒJƒ“ƒWƒ_”sŒŒÇƒ‚ƒfƒ‹‚É‚æ‚éf’f–@‚Ì•]‰¿
@@@@@3.1 ƒJƒ“ƒWƒ_”sŒŒÇ‚̐f’f
@@@@@3.2 ƒJƒ“ƒWƒ_”sŒŒÇƒ‚ƒfƒ‹‚É‚æ‚錌´f’f‚Ì•]‰¿

@ ƒ‚T„ —A‰t‚Ì—L—p«‚Æ”sŒŒÇƒ‚ƒfƒ‹‚Å‚Ì•]‰¿
@@@@1D—A‰tŽ¡—Â̌´—‚Æ”sŒŒÇ‚ÌŠÖ‚í‚è
@@@@2D”sŒŒÇƒ‚ƒfƒ‹“®•¨‚Ì‘I‘ð‚ƍ쐬|—A‰t‚Ì•]‰¿Ž–—á
@@@@3D”sŒŒÇƒ‚ƒfƒ‹“®•¨‚ð—p‚¢‚½—A‰t•]‰¿Ž–—á

@ ƒ‚U„ ƒIƒŠƒSŠjŽ_“Š—^‚É‚æ‚é”sŒŒÇ•a‘Ô‚Ì—}§‚Æ‚»‚Ì•W“I•ªŽq
@@@@1D•aŒ´‘Ì”FŽ¯‹@\
@@@@@1.1 •aŒ´‘Ì”FŽ¯Žó—e‘Ì‚Æ”sŒŒÇ‚Æ‚ÌŠÖ˜A
@@@@@1.2 ŠjŽ_”FŽ¯Žó—e‘Ì‚Æ‚»‚̃VƒOƒiƒ‹“`’B‹@\‚ɂ‚¢‚Ä
@@@@@1.3 ŠjŽ_”FŽ¯Žó—e‘ÌHMGBƒ^ƒ“ƒpƒNŽ¿‚Ì“¯’è
@@@@@@1.3.1 ”ñ–ƉuŒ´«ŠjŽ_‚É‚æ‚é–Ɖu‰ž“š—}§ì—p
@@@@@1.4 HMGB1‚Æ”sŒŒÇ‚Æ‚ÌŠÖ˜AAƒIƒŠƒSŠjŽ_“Š—^‚É‚æ‚é”sŒŒÇƒ‚ƒfƒ‹‚Ì—}§
@@@@@@1.4.1 ISM ODN‚É‚æ‚éLPS—U“±«ƒGƒ“ƒhƒgƒLƒVƒ“ƒVƒ‡ƒbƒN‚Ì—}§
@@@@@@1.4.2 ”sŒŒÇƒ‚ƒfƒ‹•a‘Ô‚ð—}§‚·‚éƒIƒŠƒSŠjŽ_‚̐«Ž¿

@ ƒ‚V„ ”MNP‰º‚̃Gƒ“ƒhƒgƒLƒVƒ“•‰‰×‚É‚æ‚étwo-hit model‚É‚æ‚é•a‘Ô‰ðÍ
@@@@@@@`Two-hit phenomenon‚ÉŠî‚¢‚½NP‰º‚É‚¨‚¯‚鐶‘Ì”½‰ž«‚̘´i`
@@@@1. Two-hit phenomenon
@@@@2. ”MNP‰º‚̃Gƒ“ƒhƒgƒLƒVƒ“•‰‰×‚É‚æ‚étwo-hit model

@ ƒ‚W„ ”sŒŒÇƒ‚ƒfƒ‹‚É‚¨‚¯‚éŽ_‰»ƒXƒgƒŒƒX‚Ì in vivo •]‰¿–@‚ÌŠJ”­
@@@@1DŽ_‰»ƒXƒgƒŒƒX‚Ì in vivo •]‰¿–@‚ÌŠJ”­
@@@@@1.1 In vivo ESR
@@@@@1.2 ESRƒCƒ[ƒWƒ“ƒO
@@@@@1.3 ƒŒƒhƒbƒNƒXƒvƒ[ƒu‚É‚æ‚éŽ_‰»ƒXƒgƒŒƒX•]‰¿
@@@@2. ”sŒŒÇƒ‚ƒfƒ‹ƒ}ƒEƒX‚̃ŒƒhƒbƒNƒX•]‰¿
@@@@@2.1 In vivo ESRƒVƒOƒiƒ‹‚̏Á’·
@@@@@2.2 Ž_‰»ƒXƒgƒŒƒX‚Ì•ª•z‚ƈӋ`

@ ƒ‚X„ ”sŒŒÇ«DICƒ‚ƒfƒ‹‚Ì“Á’¥Eì¬‚Æ•]‰¿
@@@@1D”sŒŒÇ«DIC‚Ì•a‘Ô
@@@@2D”sŒŒÇ«DIC“®•¨ƒ‚ƒfƒ‹
@@@@@2.1 “®•¨Ží‚Ì‘I‘ð
@@@@@2.2 Žä‹N•¨Ž¿‚É‚æ‚é“®•¨ƒ‚ƒfƒ‹‚ÌŠî–{“I•ª—Þ
@@@@@@2.2.1 LPS—U”­ƒ‚ƒfƒ‹
@@@@@@2.2.2 ×‹Û—U”­i‹ÛŒŒÇjƒ‚ƒfƒ‹
@@@@@@2.2.3 • –Œ‰Šƒ‚ƒfƒ‹
@@@@@@2.2.4 ‰ŠÇƒƒfƒBƒG[ƒ^[—U”­ƒ‚ƒfƒ‹
@@@@@@2.2.5 ƒ}ƒ‹ƒ`ƒqƒbƒgƒ‚ƒfƒ‹
@@@@@@2.2.6 ‚»‚Ì‘¼
@@@@3DDIC“®•¨ƒ‚ƒfƒ‹‚ÌŒÀŠE
@@@@@3.1 ŽÀŒ±“®•¨‚Ì”N—î
@@@@@3.2 ŒŒ‰tŠw“I‚¨‚æ‚ÑŒŒ‰t‹ÃŒÅü—n”\‚Ì‘Šˆá
@@@@@3.3 •ªŽqƒŒƒxƒ‹‚Å‚Ì‘Šˆá
@@@@@3.4 –òÜ‚ÌŠ´Žó«‚̈Ⴂ
@@@@@@3.4.1 –¢•ª‰æƒwƒpƒŠƒ“
@@@@@@3.4.2 ‡¬ƒvƒƒeƒA[ƒ[‘jŠQ–ò
@@@@@@3.4.3 ƒqƒgƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“iATj
@@@@@@3.4.4 ƒqƒgŠˆ«‰»ƒvƒƒeƒCƒ“CiAPCj
@@@@@@3.4.5 ƒqƒgƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“iTMj‚̈â“`Žq‘gŠ·‚¦‰Â—n«’`”’irTMj
@@@@@3.5 —Տ°‚Ƃ̘¨—£

‘æ‚RßF ŠeŠwp—̈悩‚ç‚Ý‚½¡Œã‚ÌŒ¤‹†ŠJ”­

@m‚Pn–ò—Šw“I‚ȃAƒvƒ[ƒ`‚É‚æ‚é”sŒŒÇ‚ÌŒ¤‹†ŠJ”­
@@1DRƒTƒCƒgƒJƒCƒ“Ž¡—Öò
@@@1.1 RƒTƒCƒgƒJƒCƒ“—Ö@‚É‚æ‚鐬Ñ
@@@1.2 RƒTƒCƒgƒJƒCƒ“—Ö@‚ÌŒÀŠE
@@2D“œŽ¿ƒRƒ‹ƒ`ƒRƒCƒh
@@@2.1 “œŽ¿ƒRƒ‹ƒ`ƒRƒCƒh‚̍ì—p‹@˜
@@@2.2 ”sŒŒÇ‚ɑ΂·‚éƒXƒeƒƒCƒhŽ¡—Â̍l‚¦•û
@@3DŠˆ«Œ^ƒvƒƒeƒCƒ“C
@@@3.1 Šˆ«Œ^ƒvƒƒeƒCƒ“C‚̐¶—‹@”\
@@@3.2 Šˆ«Œ^ƒvƒƒeƒCƒ“C‚Ì”sŒŒÇŽ¡—Âɑ΂·‚é•]‰¿
@@4DƒGƒŠƒgƒ‰ƒ“
@@@4.1 LPS‚ÆTLR4
@@@4.2 ƒGƒŠƒgƒ‰ƒ“‚̗Տ°ŽŽŒ±

@m‚Qn”sŒŒÇ‚Ì•a—E•a‘Ԑ¶—Šw“I‚ȃAƒvƒ[ƒ`‚É‚æ‚錤‹†ŠJ”­
@@1D”sŒŒÇ‚Æ‚»‚Ì•ª—Þ
@@@1.1 ”sŒŒÇ‚Æ‚Í
@@@1.2 ”sŒŒÇ«ƒVƒ‡ƒbƒNiseptic shockj
@@@1.3 ‘Sg«‰ŠÇ”½‰žÇŒóŒQiSIRS)systemic inflammatory response syndrome
@@2D”sŒŒÇ‚ÌŒ´ˆö•a‘ƒ
@@@2.1 Š´õ«S“à–Œ‰Š infective endocarditis
@@@2.2 ”sŒŒÇ‚Ì•a—ŠŒ©

@m‚Rn–ƉuŠw“I‚É‚Ý‚½”sŒŒÇ‚Ì•a‘Ô‚ÆŒ¤‹†“®Œü
@@1D”sŒŒÇ‚É‚¨‚¯‚é–Ɖu‰ž“š
@@@1.1 Š´õ‚É‚¨‚¯‚é–Ɖu‰ž“š
@@@1.2 Ž©‘R–Ɖu‰ž“š‚ÉŠÖ—^‚·‚é×–EŒQ
@@@1.3 ƒTƒCƒgƒJƒCƒ“ƒXƒg[ƒ€
@@@1.4 Ž©‘R–Ɖu‰ž“š‚ÉŠÖ—^‚·‚镪ŽqŒQ
@@@1.5 –Ɖu’S“–×–E‚̃Aƒ|ƒg[ƒVƒX‚É”º‚¤–Ɖu—}§ó‘Ô
@@2D”sŒŒÇ‚É‚¨‚¯‚é–ƉuŠw“IŒ¤‹†
@@@2.1 ”ì–ž×–E
@@@2.2 ƒCƒ“ƒtƒ‰ƒ}ƒ\[ƒ€
@@@2.3 ¡Œã‚ÌŽ¡—Ã^[ƒQƒbƒg

@m‚Sn»ÜŠw“IƒAƒvƒ[ƒ`‚É‚æ‚é”sŒŒÇŽ¡—Â̌¤‹†ŠJ”­
@@@@@@`RŽ_‰»Ü‚ÌDDSŠJ”­‚Æ”sŒŒÇŽ¡—Âւ̉ž—p`
@@1DRŽ_‰»Ü‚ÌDDSŠJ”­
@@@1.1 ŠÒŒ³Œ^ƒ`ƒI[ƒ‹‚̍RŽ_‰»Œø‰Ê‘‹­‚ð–ÚŽw‚µ‚½ŠÒŒ³Œ^ƒ`ƒI[ƒ‹CüƒAƒ‹ƒuƒ~ƒ“‚ÌŠJ”­
@@@1.2 ROSÁ‹Ž”\‚É—D‚ê‚éƒvƒ‰ƒ`ƒiƒiƒm—±Žq‚ÌŠJ”­
@@2D‚¨‚í‚è‚É

‘æ‚SßF ”sŒŒÇŒ¤‹†‚Ì‚½‚߂̃Gƒ“ƒhƒgƒLƒVƒ“’è—Ê–@‚ÌŠJ”­‚Æ•]‰¿
@1DƒJƒuƒgƒKƒjŒŒ‹…’Šo‰t‚ð‚à‚¿‚¢‚½ƒGƒ“ƒhƒgƒLƒVƒ“‚Ì’è—Ê–@
@@1.1 ƒGƒ“ƒhƒgƒLƒVƒ“‚É“ÁˆÙ“I‚ȃŠƒ€ƒ‹ƒXƒeƒXƒg
@@1.2 ŒŒŸ÷‚Ì‘Oˆ—–@
@@@1.2.1 ‰ß‰–‘fŽ_ˆ—–@iPCA–@j
@@@1.2.2 New PCAˆ—–@
@@@1.2.3 ƒAƒ‹ƒJƒŠˆ—–@
@@@1.2.4 ŠóŽß‰Á”M–@‚¨‚æ‚Ñ‚»‚Ì•Ï–@
@@1.3 ”ä‘÷ŽžŠÔ•ªÍ–@
@@1.4 ƒŒ[ƒU[ŽU—Œõ•ªÍ–@
@@1.5 ŒuŒõ–@
@@1.6 ”’ŒŒ‹…ƒGƒ“ƒhƒgƒLƒVƒ“‚Ì’è—Ê–@
@2D¶‘Ì‘¤—vˆö‚©‚猩‚½ƒGƒ“ƒhƒgƒLƒVƒ“‘ª’è‚ɂ‚¢‚Ă̍lŽ@
@3DEndotoxin activity assayiEAAj‚Æ‚»‚Ì–â‘è“_
@@3.1 •û–@‚ÌŒ´—
@@3.2 –â‘è“_
@4DƒGƒ“ƒhƒgƒLƒVƒ“‚Ì–ðŠ„‚É‘Î‚·‚é–{–M‚Ɖ¢•Ä‚Ì”FŽ¯‚̈Ⴂ


Ÿ ‘æ‚QÍF”sŒŒÇ‚̃oƒCƒIƒ}[ƒJ[‚ÌŠJ”­ @ 

‘æ‚PßF ”sŒŒÇƒoƒCƒIƒ}[ƒJ[‚ÌŒ¤‹†E’Tõ

@m‚Pn‰ŠÇ«ƒ}[ƒJ[
@ ƒ‚P„ ƒTƒCƒgƒJƒCƒ“
@@@@1. ƒTƒCƒgƒJƒCƒ“‚Ì’è‹`
@@@@2. ”sŒŒÇ‚Ì•a‘Ô
@@@@3. ƒTƒCƒgƒJƒCƒ“‚ÌŽí—Þ‚Æ“Á’¥
@@@@@3.1 ƒCƒ“ƒ^[ƒƒCƒLƒ“(ILFinterleukin)
@@@@@3.2 TNFitumor necrosis factorFŽîᇉ󎀈öŽqj
@@@@@3.3 ƒPƒ‚ƒJƒCƒ“
@@@@@3.4 ƒCƒ“ƒ^[ƒtƒFƒƒ“
@@@@@4.5 G-CSF
@@@@4. ”sŒŒÇŽž‚̃TƒCƒgƒJƒCƒ“‚̕ω»
@@@@5. ”sŒŒÇ‚ɑ΂·‚éRƒTƒCƒgƒJƒCƒ“—Ö@
@@@@6. ”sŒŒÇ‚ɑ΂·‚éV‹K–ò•¨—Ö@
@@@@7. ¡Œã‚Ì“W–]

@ ƒ‚Q„ ƒvƒƒJƒ‹ƒVƒgƒjƒ“
@@@@1. ƒvƒƒJƒ‹ƒVƒgƒjƒ“‚Æ‚Í
@@@@2. ”sŒŒÇ‚ÌŠT”O
@@@@3. ”sŒŒÇ‚̐f’f‚ÌŒ»‹µ
@@@@4. ƒvƒƒJƒ‹ƒVƒgƒjƒ“‚̗Տ°“I—L—p«
@@@@5. ƒvƒƒJƒ‹ƒVƒgƒjƒ“‚ƍR‹Û–ò“Š—^

@ ƒ‚R„ ƒvƒŒƒZƒvƒVƒ“
@@@@1DƒvƒŒƒZƒvƒVƒ“ŠJ”­‚ÌŒoˆÜ‚Æ‘ª’è•û–@
@@@@2D—Տ°•a‘Ô‚É‚¨‚¯‚éƒvƒŒƒZƒvƒVƒ“
@@@@@2.1 ƒvƒŒƒZƒvƒVƒ“‚ÌŠ´“x“ÁˆÙ“x
@@@@@2.2 dÇ“xŽw•W‚Æ‚µ‚ẴvƒŒƒZƒvƒVƒ“
@@@@@2.3 Œ´ˆö•aŒ´‘̕ʂ̃vƒŒƒZƒvƒVƒ“
@@@@@2.4 ŽüpŠú‚É‚¨‚¯‚éƒvƒŒƒZƒvƒVƒ“
@@@@@2.5 ƒvƒŒƒZƒvƒVƒ“‘ª’è‚Ì—L—p«‚ªŠú‘Ò‚³‚ê‚é—̈æ

@ ƒ‚S„ ƒyƒ“ƒgƒ‰ƒLƒVƒ“‚R
@@@@1Dƒyƒ“ƒgƒ‰ƒLƒVƒ“‚RiPTX3j
@@@@@1.1 ƒQƒmƒ€
@@@@@1.2 •ªŽq\‘¢
@@@@@1.3 ”­Œ»•”ˆÊ
@@@@@1.4 ‹@”\
@@@@@1.5 Œ‹‡ƒ^ƒ“ƒpƒN
@@@@@1.6 ŒŒ’†”Z“x
@@@@2DNeutrophil extracellular traps (NETs)
@@@@@2.1 NETs‚Ì‹Ÿ‹‹Œ¹A”­Œ»‚¨‚æ‚Ñ‚»‚Ì‹@”\
@@@@@2.2 NETs\¬ƒ^ƒ“ƒpƒNŽ¿
@@@@3D”sŒŒÇŒŒ’†PTX3”Z“x‚Æ”sŒŒÇf’f‚̉”\«
@@@@@3.1 ”sŒŒÇ‚É‚¨‚¯‚錌’†PTX3”Z“x
@@@@@3.2 ”sŒŒÇŒŒ’†PTX3‚ÌNETs\¬ƒ^ƒ“ƒpƒN‚Æ‚Ì•¡‡‘ÌŒ`¬‚Ɛf’f‰ž—p‚̉”\«
@@@@4DŒ‹Œê

@m‚QnEAA(Endotoxin activity assay)ƒ}[ƒJ[
@@1. EAA‚Æ‚Í‚Ç‚ñ‚ÈŽŽ–ò‚©
@@@1.1 ‘ª’茴—
@@@1.2 ‘ª’èŽè‡
@@@1.3 ƒpƒ‰ƒ[ƒ^
@@@@1.3.1@Response
@@@@1.3.2@CVi•Ï“®ŒW”j%
@@@@1.3.3@”’ŒŒ‹…”
@@@1.4 Œ‹‰Ê‚̉ðŽß
@@2. ‘¼‚Ì”sŒŒÇ€–Ú‚Æ‚Ì”äŠr

@m‚RnŒŒ‰t‹ÃŒÅƒ}[ƒJ[
@ ƒ‚P„ ƒvƒƒeƒCƒ“‚b‚Ì—\Œã—\‘ªƒ}[ƒJ[‚Æ‚µ‚Ä‚Ì—L—p«
@@@@1. ƒvƒƒeƒCƒ“C§ŒäŒn
@@@@2. Šˆ«‰»ƒvƒƒeƒCƒ“C
@@@@@2.1 ŒŒŠÇ“à”ç×–Eã‚ÌPCŽó—e‘̂ƃvƒƒeƒA[ƒ[Šˆ«‰»Žó—e‘Ì
@@@@@2.2 ƒXƒtƒBƒ“ƒSƒVƒ“1ƒŠƒ“Ž_‚Ƃ̃XƒtƒBƒ“ƒSƒVƒ“1ƒŠƒ“Ž_Žó—e‘Ì
@@@@@2.3 Apolipoprotein E receptor-2
@@@@@2.4 Glycoprotein IbiGPIbj
@@@@@2.5 ƒCƒ“ƒeƒOƒŠƒ“
@@@@@2.6 High Mobility Group Box 1
@@@@@2.7 ƒqƒXƒgƒ“
@@@@3. ”sŒŒÇ‚Ì•a‘Ô
@@@@4. APC‚̗Տ°Œø‰Ê

@ ƒ‚Q„ ”sŒŒÇ‚Ævon Willebrand ˆöŽqŠÖ˜AˆöŽq@`ADAMTS13‚𒆐S‚Ɂ`
@@@@1. VWF‚ÆADAMTS13‚Ì‹@”\
@@@@@1.1 VWF‚Ì‹@”\
@@@@@1.2 ADAMTS13‚Ì‹@”\
@@@@@@1.2.1 •ª”傳‚ꂽVWF‚Ì’·‚³’²ß
@@@@@@1.2.2 ŒŒð“àoi“W§Œä‹@”\
@@@@@@1.2.3 R‰ŠÇì—p
@@@@2. ”sŒŒÇ
@@@@@2.1 ”sŒŒÇ‚ÆVWFŠÖ˜AˆöŽq
@@@@@@2.1.1 ”sŒŒÇ‚ÆVWF
@@@@@2.2 ”sŒŒÇ‚ÆADAMTS13
@@@@@@2.2.1 ”sŒŒÇ‚ÆŒŒ’†ADAMTS13”Z“x
@@@@@@2.2.2 ”sŒŒÇ‚É‚¨‚¯‚éADAMTS13”Z“x’ቺ‚ÌŒ´ˆö
@@@@@@2.2.3 ”sŒŒÇ‚É‚¨‚¯‚éADAMTS13”Z“x’ቺ‚̈Ӌ`
@@@@@2.3 ADAMTS13‚ÆVWF•ª”å‚̃Aƒ“ƒoƒ‰ƒ“ƒX

‘æ‚QßF Ž¡—Â̗\Œã—\‘ª‚Ì–Ê‚©‚ç‚Ý‚½ƒ}[ƒJ[‚Ì’Tõ‚ÆŠJ”­

@m‚PnŠ³ŽÒ––½ŒŒƒŠƒ“ƒp‹…‚Ì‘B”\‚ƃXƒeƒƒCƒhŠ´Žó«‚ÉŠî‚­”sŒŒÇ”­ÇƒŠƒXƒN—\‘ª‚̉”\«
@@1D”sŒŒÇŠ³ŽÒ‚ÆŒ’íŽÒŠÔ‚É‚¨‚¯‚é––½ŒŒ’PŠj×–EiPBMCj‚̃}ƒCƒgƒQƒ“‰ž“š«‘B”\‚̈Ⴂ
@@@1.1 PBMC‘B‚̃}ƒCƒgƒQƒ“ƒAƒbƒZƒC–@
@@@1.2 ”sŒŒÇŠ³ŽÒPBMC‚É‚¨‚¯‚鑝B”\‚̒ቺ
@@2D”sŒŒÇŠ³ŽÒ‚ÆŒ’íŽÒŠÔ‚É‚¨‚¯‚éPBMC‚̃Oƒ‹ƒRƒRƒ‹ƒ`ƒRƒCƒhŠ´Žó«‚̈Ⴂ
@@3DŠ³ŽÒ––½ŒŒPBMCŠˆ«‚ÉŠî‚­”sŒŒÇ”­ÇƒŠƒXƒN—\‘ª‚̉”\«


Ÿ ‘æ‚RÍF”sŒŒÇ‚ÌŒŸ¸‚Ɛf’f–òEf’f‹Zp‚ÌŠJ”­ @ 

‘æ‚PßF ”sŒŒÇ‚ÌŒŸ¸‚Ɛf’f‚ÌŽÀî

@m‚Pn”sŒŒÇŠ³ŽÒ‚̗Տ°ŒŸ¸’l‚Ì“Á’¥
@@@@@@@`”’ŒŒ‹…ACRPAŒŒ¬”‚¨‚æ‚уtƒBƒuƒŠƒmƒQƒ“‚ÌŠˆ—p`
@@1D×‹ÛŠ´õÇ‚̐f’f‚É—p‚¢‚é—Տ°ŒŸ¸
@@@1.1 ƒ‹[ƒ`ƒ“ŒŸ¸‚Őf’f‚·‚邽‚߂̍׋ۊ´õÇ‚Ì’è‹`
@@@1.2 D’†‹…‚Æ”’ŒŒ‹…
@@@1.3 ×‹ÛŠ´õÇ‚É‚¨‚¯‚éD’†‹…@(”’ŒŒ‹…)@‚Ì“®‚«
@@@@1.3.1 Š´õ’¼Œã
@@@@1.3.2 1-2ŽžŠÔŒo‰ß
@@@@1.3.3 12-24ŽžŠÔŒo‰ß
@@@@1.3.4 D’†‹…‚ª×‹Û‚ɑΏˆ‚·‚鎞Šú
@@@1.4 ¶•ûˆÚ“®
@@@1.5 ”’ŒŒ‹…”‚¨‚æ‚э¶•ûˆÚ“®‚©‚犴õÇ‚Ì•a‘Ô‚ð—ސ„‚·‚é
@@@@1.5.1 ”’ŒŒ‹…iàD’†‹…j‘‰Á + ¶•ûˆÚ“®i-j
@@@@1.5.2 ”’ŒŒ‹…‘‰Á + ¶•ûˆÚ“®i+j
@@@@1.5.3 ”’ŒŒ‹…”’ቺ@+ ¶•ûˆÚ“®i-j
@@@@1.5.4 ”’ŒŒ‹…”’ቺ@+ ¶•ûˆÚ“®i+j
@@@1.6 D’†‹…Á”­‚È‚¢dÇŠ´õÇ
@@@@1.6.1 Š´õ«S“à–Œ‰Š
@@@@1.6.2 ×‹Û«‘–Œ‰Š
@@@@1.6.3 ”^á‡
@@2D”sŒŒÇ‚̐f’f‚É—p‚¢‚é—Տ°ŒŸ¸
@@@2.1 ƒ‹[ƒ`ƒ“iŠî–{“Ij—Տ°ŒŸ¸‚Å”sŒŒÇ‚ðf’f‚·‚é’è‹`
@@@2.2 ŒŒ¬”Â
@@@2.3 ŒŒ¬”ÂŒ¸­‚̃ƒJƒjƒYƒ€
@@@2.4 ƒtƒBƒuƒŠƒmƒQƒ“
@@3DŽÀÛ‚ÌŒŸ¸’l‚Ì“®‚«
@@@3.1 Ç—áFt᱉Š + ”sŒŒÇ
@@@3.2 ”’ŒŒ‹…”‚Æ”’ŒŒ‹…•ª‰æ
@@@3.3 ŒŒ¬”Â
@@@3.4 ƒtƒBƒuƒŠƒmƒQƒ“
@@@3.5 Ç—á‚̍lŽ@
@@4D‚Ü‚Æ‚ß

@m‚Qn”sŒŒÇŒŒ‰t”|—{ŒŸ¸‚ÌŽÀÛ
@@1. ŒŸ¸‚Ì–Ú“I
@@2. ŒŒ‰t”|—{‚̃^ƒCƒ~ƒ“ƒO
@@3. ŒŒ‰t”|—{‚̎菇‚ÌŽÀÛ
@@4. ŒŒ‰t”|—{‚É•K—v‚ÈŒŒ‰t—ʂƃZƒbƒg”
@@5. ƒRƒ“ƒ^ƒ~ƒl[ƒVƒ‡ƒ“‚̉”\«‚ÆŒ‹‰Ê‚̉ðŽß

@m‚Rn”sŒŒÇ‚̐f’f‚ÌŒ»ó
@@1. PCT
@@@1.1 PCT‚Ì‘ª’肨‚æ‚уJƒbƒgƒIƒt’l
@@@1.2 ‘Sg«×‹ÛŠ´õÇ‚̐f’fƒ}[ƒJ[‚¨‚æ‚яdÇ“x”»’è‚Æ‚µ‚Ä‚Ì—L—p«
@@@1.3 –{–M‚É‚¨‚¯‚鑽Ž{Ý‹¤“¯Œ¤‹†
@@@1.4 ‹Nˆö‹Û‚ÌŽí—Þ‚É‚¨‚¯‚éPCT
@@@1.5 ƒXƒeƒƒCƒh“Š—^Ç—á‚É‚¨‚¯‚é×‹ÛŠ´õÇdÇ“x”»’è‚Ì—L—p«
@@@1.6 • –Œ‰ŠÇ—á‚É‚¨‚¯‚é—L—p«
@@2. ”’ŒŒ‹…’†×‹ÛŠjŽ_“¯’茟¸
@@3. ƒGƒ“ƒhƒgƒLƒVƒ“‘ª’è
@@@3.1 ƒJƒuƒgƒKƒjŒŒ‹…’Šo¬•ª‚ð—p‚¢‚½ƒGƒ“ƒhƒgƒLƒVƒ“‘ª’è
@@@3.2 LAL–@‚É‚¨‚¯‚éƒGƒ“ƒhƒgƒLƒVƒ“‘ª’è‚Ì–â‘è“_
@@@3.3 Endotoxin Activity Assay‚É‚æ‚éƒGƒ“ƒhƒgƒLƒVƒ“‘ª’è
@@@3.4 EAA‚É‚æ‚é×‹ÛŠ´õÇf’f

‘æ‚QßF f’fEŒŸ¸‹Zp‚ÌŒ¤‹†ŠJ”­“®Œü

@m‚Pn”÷¶•¨“¯’茟¸»•i‚ÌŠJ”­Ž–—á‚Æ—ðŽj
@@1D¶‰»Šw“I«ó‚ÉŠî‚­”÷¶•¨“¯’茟¸
@@@1.1 APIƒVƒŠ[ƒY‚Ì’a¶
@@@1.2 ƒf[ƒ^ƒx[ƒX‚̃Rƒ“ƒsƒ…[ƒ^[‰»‚Ɛ”’l“¯’è‚ðŽg‚Á‚½ƒAƒ‹ƒSƒŠƒYƒ€‰ðÍ
@@@1.3 ¶‰»Šw“I«ó‚ð—p‚¢‚½“¯’莎Œ±‚ÌŽ©“®‰» - ƒoƒCƒeƒbƒNƒVƒŠ[ƒY
@@@1.4 Ž©“®‘•’u‚Ì‘ª’茴—‚ƃAƒ‹ƒSƒŠƒYƒ€‰ðÍ
@@2DŽ¿—Ê•ªÍ‹Zp‚ð—p‚¢‚½”÷¶•¨“¯’茟¸
@@@2.1 ”÷¶•¨“¯’è‚É—p‚¢‚鎿—Ê•ªÍŒv - MALDI-TOF MS|
@@@@2.1.1 MALDI-TOF‚ÌŒ´—
@@@@@@- ƒCƒIƒ“‰»–@ - MALDI‚Æ‚Í
@@@@@@- •ª—£–@ - TOF‚Æ‚Í
@@@@2.1.2 MALDI-TOF MS‚É‚æ‚é”÷¶•¨“¯’è‚̃[ƒNƒtƒ[
@@@2.2 ƒf[ƒ^ƒx[ƒX‚ƃAƒ‹ƒSƒŠƒYƒ€‰ðÍ

@m‚QnŒŒ‰t”|—{‚Ì—v‹‚ÆŽ©“®ŒŒ‰t”|—{‘•’uBD ƒoƒNƒeƒbƒN‚ÌŠJ”­
@@1. ŒŒ‰t”|—{
@@2. ŒŒ‰t”|—{‚̃|ƒCƒ“ƒg
@@3. ŒŒ‰t”|—{ƒ{ƒgƒ‹‚ÌŠJ”­
@@4. ŒŒ‰t”|—{‘•’u‚ÌŠJ”­

@m‚Rn”sŒŒÇ‚ÌDNAƒ`ƒbƒv‚ÌŠJ”­
@@1. •û–@
@@@1.1 ‹¤’ʃvƒ‰ƒCƒ}[—̈æ‚Æ‹Û“ÁˆÙ“Iƒvƒ[ƒu—̈æ
@@@1.2 ƒ}ƒCƒNƒƒAƒŒƒC‰ðÍ
@@2. Œ‹‰Ê
@@@2.1 ‹ÛŠ”‚Ì16S rDNAƒAƒ‰ƒCƒƒ“ƒg‚Æ‹¤’ʃvƒ‰ƒCƒ}[‚Ì‘I’è
@@@2.2 ‹¤’ʃvƒ‰ƒCƒ}[‚ð—p‚¢‚½PCR‚É‚æ‚é‹ÛŠ”‚Ì“¯’è
@@@2.3 PCRŽY•¨‚ð—p‚¢‚½DNAƒ`ƒbƒv‰ðÍ

@m‚Sn”sŒŒÇ‹N‰Š‹Ûv‘¬“¯’èƒVƒXƒeƒ€‚ÌŠJ”­ `Tm mapping–@`
@@1. Š´õÇ‹N‰Š‹Ûv‘¬“¯’èƒVƒXƒeƒ€‚ÌŠT—v
@@2. V‚½‚È‹N‰Š‹Ûv‘¬“¯’è•û–@GTm mapping–@
@@3. ‹N‰Š‹Û“¯’èƒ\ƒtƒgƒEƒFƒA
@@4. –{ƒVƒXƒeƒ€‚Ì”»’èŠî€‚Ɛ³Šm«‚Ì•]‰¿
@@5. Tm mapping–@‚Ì—˜“_‚¨‚æ‚э¡Œã‚̉ۑè

‘æ‚RßF f’f–òEf’f‹@ŠíEŽŽ–ò‚ÌŠJ”­Ž–—á

@m‚Pn—Տ°«”\ŽŽŒ±‚Æ–òŽ–‚̑Ήž
@@1. —Տ°«”\ŽŽŒ±
@@2. ŽŽŒ±ŽÀŽ{Œv‰æ‘
@@3. Ç—á•ñ‘
@@4. “¯ˆÓà–¾•¶‘A“¯ˆÓ‘
@@5. —Տ°ŽŽŒ±‚Æ‚Í
@@6. –òŽ–\¿‚ÌŠT—ª

@m‚QnƒPƒ~ƒ‹ƒ~BRAHMSƒvƒƒJƒ‹ƒVƒgƒjƒ“ ‚ÌŠJ”­Ž–—á
@@@@ @`‚æ‚è“ÁˆÙ«‚̍‚‚¢ƒvƒƒJƒ‹ƒVƒgƒjƒ“‘ª’è•û–@‚ð‚ß‚´‚µ‚ā`
@@1.uƒPƒ~ƒ‹ƒ~BRAHMSƒvƒƒJƒ‹ƒVƒgƒjƒ“v‚ÌŠT—v
@@@1.1 ‘ª’莎–ò
@@@1.2 ‘ª’è–@ŠT—v
@@2.uƒPƒ~ƒ‹ƒ~BRAHMSƒvƒƒJƒ‹ƒVƒgƒjƒ“v‚ÌŠî–{«”\
@@@2.1 ÄŒ»«
@@@2.2 ŒŸoŠ´“x
@@@2.3 ŠóŽß’¼ü«
@@@2.4 ‘ŠŠÖ«
@@3.uƒPƒ~ƒ‹ƒ~BRAHMSƒvƒƒJƒ‹ƒVƒgƒjƒ“v‚ÌŠeŽíƒf[ƒ^
@@@3.1 —V—£ƒJƒ‹ƒVƒgƒjƒ“‚̉e‹¿
@@@3.2 N––’[PCT‚̉e‹¿

@m‚RnƒCƒ€ƒmƒNƒƒ}ƒg–@‚É‚æ‚éƒvƒƒJƒ‹ƒVƒgƒjƒ“‚Ì‘ª’è–@
@@1. ŽŽ–ò\¬
@@2. ‘ª’茴—
@@3. ŽŽ–ò‚̍\‘¢
@@4. ŽŽ–ò‚ÌŽg—p•û–@

‘æ‚SßF —Տ°‚ł̐f’f‚ÌŒ»ó‚ÆŽŸ¢‘ã‚̐f’f‹Zp‚ª‚à‚½‚ç‚·f’fEŽ¡—Â̗¬‚ê‚̕ω»—\‘ª

@m‚Pn‘Ûˆã—ÕŸŽƒ‘åŠw•a‰@”MŠC•a‰@‚ł̗Տ°ŒŸ¸Ef’f‚ÌŒ»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1DŒ»Ý‚̐f’f‚ÌŒ»ó
@@@1.1 f’fEŒŸ¸‚ÌŒ»ó
@@@1.2 ƒoƒCƒIƒ}[ƒJ[‚Ɛf’f–òEf’f‹@Ší‚ÌŒ»ó
@@@1.3 Œ´ˆö‹Û‚ÌŒŸoE“¯’è–@
@@2Df’fEŒŸ¸‹ZpAƒoƒCƒIƒ}[ƒJ[‚ÌŒ¤‹†ŠJ”­‚Ì“®Œü‚Ɛf’f‚̕ω»—\‘ª
@@@2.1 ‚T”NŒã‚̐f’fEŽ¡—ÁE‹@Ší‚Ì‘I‘ð—\‘ª
@@@@@@@(Œ»ÝŠJ”­’†‚Ì‹Zp‚ÌŽÀ—p‰»‚ª”äŠr“Ii“W‚µ‚½ê‡)
@@@2.2 ‚T”NŒã‚̐f’fEŽ¡—ÁE‹@Ší‚Ì‘I‘ð—\‘ª
@@@@@@@(Œ»ÝŠJ”­’†‚Ì‹Zp‚ÌŽÀ—p‰»‚ª”äŠr“Ii“W‚µ‚È‚¢ê‡)

@m‚Qn’·è‘åŠw•a‰@‚ł̗Տ°ŒŸ¸Ef’f‚ÌŒ»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1DŒ»Ý‚̐f’f‚ÌŒ»ó
@@@1.1 f’fEŒŸ¸‚ÌŒ»ó
@@@1.2 ƒoƒCƒIƒ}[ƒJ[‚Ɛf’f–òEf’f‹@Ší‚ÌŒ»ó
@@@1.3 Œ´ˆö‹Û‚ÌŒŸoE“¯’è–@
@@@@1.3.1 ŒŒ‰t”|—{‚̉ñ”‚¨‚æ‚Ñ—Ê
@@2Df’fEŒŸ¸‹ZpAƒoƒCƒIƒ}[ƒJ[‚ÌŒ¤‹†ŠJ”­‚Ì“®Œü‚Ɛf’f‚̕ω»—\‘ª
@@@2.1 ‚T”NŒã‚̐f’fEŽ¡—ÁE‹@Ší‚Ì‘I‘ð—\‘ª
@@@2.2 10”NŒã‚ÌŽ¡—ÁE–òÜE‹@Ší‚Ì‘I‘ð—\‘ª

@m‚RnŒà‹¤Ï•a‰@‚ł̗Տ°ŒŸ¸Ef’f‚ÌŒ»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@@@@@`”sŒŒÇƒ}[ƒJ[FƒvƒƒJƒ‹ƒVƒgƒjƒ“‘ª’è‚̗Տ°‚ւ̉ž—p`
@@1. ƒvƒƒJƒ‹ƒVƒgƒjƒ“v‘¬ƒLƒbƒgF PCT-Q‚̗Տ°‚ւ̉ž—p
@@@1.1 PCT-Q‚Å‚ÌŒŒ‰t”|—{‚ÆSIRS”»’è‚©‚ç‚Ì”äŠrŒŸ“¢‚©‚ç‚̃Aƒvƒ[ƒ`
@@@1.2 PCT-Q‚Ì—L—p«
@@@1.3 PCT-Q‚Ì–â‘è“_
@@@1.4 v‘¬ƒLƒbƒgPCT-QŽg—p‚̃|ƒCƒ“ƒg‚Ì‚Ü‚Æ‚ß
@@2. ƒvƒƒJƒ‹ƒVƒgƒjƒ“’è—Ê‘ª’è‚̗Տ°“I—L—p«
@@@2.1 Ç—á‚©‚ç‚ÌŒŸ“¢- PCT‚Ì—§‚¿ã‚ª‚è‚Æ‘¼‚̉ŠÇƒ}[ƒJ[‚Æ‚Ì”äŠr
@@@2.2 PCT’è—Ê‘ª’è‚É‚æ‚é“®‘Ô”cˆ¬‚ªR‹Û–òŽ¡—ÂɍvŒ£‚Å‚«‚½Ç—á
@@@2.3 ŒŒ‰t”|—{ŒŸ¸‚̕⏕“IŒŸ¸‚Æ‚µ‚Ä‚ÌPCT‚Æ‚»‚Ì‘¼‰ŠÇƒ}[ƒJ[‚Æ‚ÌŠÖ˜A«‚ɂ‚¢‚Ä


Ÿ ‘æ‚SÍFŒŒ‰tò‰»—Ö@A•a‘Ôƒ‚ƒjƒ^ƒŠƒ“ƒO‚ƈã—Íޗ¿E‹@ŠíŠJ”­ @ 
‘æ‚PßF ”sŒŒÇ‚ɑ΂·‚錌‰tò‰»–@‚Ì—˜_‚ÆŒ»ó
@1DŒŒ‰tò‰»–@‚Æ‚Í
@2DŒŒ‰tò‰»–@‚É‚æ‚镨Ž¿‚̏œ‹Ž
@3D”sŒŒÇ‚ɑ΂·‚錌‰tò‰»–@‚Ì—˜_‚ÆŽÀÛ
@4D”sŒŒÇ‚É‚¨‚¯‚錌‰tò‰»–@‚ÌŠJŽnŽžŠú
@5DŒŒ‰tò‰»–@‚ÉŠÖ‚í‚é‹@ŠíŠJ”­‚̃|ƒCƒ“ƒg

‘æ‚QßF ŒŒ’†ƒGƒ“ƒhƒgƒLƒVƒ“‹z’…Þ—¿‚ÌŠî–{ÝŒv‚Ɛ«”\•]‰¿
@1. ‹z’…Þ—¿‚̐݌v
@2. ŒŒ‰t‹z’…ƒJƒ‰ƒ€ŠJ”­‚̐i•à
@@2.1@—Տ°•]‰¿‚³‚ꂽŒŒ‰t‹z’…ƒJƒ‰ƒ€
@@@-ƒqƒgŒŒ´ƒAƒ‹ƒuƒ~ƒ“ŒÅ’艻ƒJƒ‰ƒ€igMATISSEhj
@@@-DEAE|ƒZƒ‹ƒ[ƒXƒJƒ‰ƒ€
@@@-ƒAƒ‹ƒMƒjƒ“ŒÅ’艻ƒJƒ‰ƒ€
@3DŒ»Ý—Տ°Žg—p‚³‚ê‚Ä‚¢‚錌’†ƒGƒ“ƒhƒgƒLƒVƒ“‹z’…ƒJƒ‰ƒ€
@@3.1 Alteco(R)@LPS Adsorber
@@3.2 ƒgƒŒƒ~ƒLƒVƒ“(R)
@@@-‹z’…ÞAƒJƒ‰ƒ€‚̐݌v
@@@-—Տ°Œø‰Ê
@@@-—Տ°ŽŽŒ±‚̐¬Ñ

‘æ‚RßF ƒƒfƒBƒG[ƒ^EƒTƒCƒgƒJƒCƒ“‚Ì‹z’…Eœ‹Ž‚Æ‚»‚Ì•]‰¿
@1D”sŒŒÇ‚É‚¨‚¯‚郁ƒfƒBƒG[ƒ^§Œä‚ÆŒŒ‰tò‰»—Ö@
@@1.1 ‰ä‚ª‘‚É‚¨‚¯‚郁ƒfƒBƒG[ƒ^§Œä‚ɑ΂·‚錌‰tò‰»—Ö@‚Ì—ðŽj
@@1.2 The peak Concentration Hypothesis
@@1.3 ƒƒfƒBƒG[ƒ^œ‹ŽŒø—¦
@2D–{–M‚É‚¨‚¯‚郁ƒfƒBƒG[ƒ^§Œä‚É‚¨‚¯‚é‹z’…–Œ‚ÌŒ»Ý‚Æ–¢—ˆ
@3DƒƒfƒBƒG[ƒ^‹z’…Eœ‹Ž‚Æ–â‘è“_

‘æ‚SßF ŒŒ‰t“§ÍŠíEŒŒ‰t“§Íàh‰ßŠíEŽ‘±ŠÉ™Ž®ŒŒ‰tàh‰ßŠí‚ÌŠJ”­Ž–—á
@1Dˆ®‰»¬ƒOƒ‹[ƒv‚ÌŒŒ‰t“§Í–Œ‹Zp
@@1.1 V‹KŒŒ‰t“§Í–Œ‚ÌŠJ”­ƒj[ƒY
@@1.2 ‘åEŒa‚©‚ƒVƒƒ[ƒv‚È•ªŽq—Ê•ª‰æ“Á«‚ÌŽÀŒ»
@@1.3 —ǍD‚ÈŒŒ‰t“K‡«‚Æ—no•¨‚ª­‚È‚­—ǍD‚ȈÀ‘S«‚Ì—¼—§‚ÌŽÀŒ»
@@1.4 “ÆŽ©‹Zp‚É‚æ‚錌‰t“§ÍŠí‚̗Տ°Œø‰Ê
@2D”sŒŒÇ‚ÉŽg—p‚³‚ê‚錌‰t“§Íàh‰ßŠíAŽ‘±ŠÉ™Ž®ŒŒ‰tàh‰ßŠí
@@2.1 ŒŒ‰t“§Íàh‰ßŠí
@@2.2 Ž‘±ŠÉ™Ž®ŒŒ‰tàh‰ßŠí

‘æ‚TßF •a‘Ôƒ‚ƒjƒ^ƒŠƒ“ƒO‹Zp‚Æ‘•’uŠJ”­

@m‚Pn”sŒŒÇ‚̌ċzŠÇ—AŒŒ‰tE‘ãŽÓ‚̃‚ƒjƒ^ƒŠƒ“ƒO‹Zp
@@1D”sŒŒÇ‚Ì•a‘Ô
@@@1.1 ”sŒŒÇ‚ÌŠT”OA’è‹`
@@@1.2 ”sŒŒÇ‚Ì•aˆö
@@@1.3 ”sŒŒÇ«ƒVƒ‡ƒbƒNiseptic shockj
@@@@1.3.1 ŠT”O
@@@@1.3.2 •a‘Ô
@@@@1.3.3 Ž¡—Ã
@@@1.4 ‹}«ŒÄ‹z‹‡”—ÇŒóŒQiARDSj
@@@@1.4.1 ŠT”O
@@@@1.4.2 ŒŸ¸ŠŒ©
@@@@@@- “®–¬ŒŒƒKƒX•ªÍ
@@@@@@- ‹¹•”ƒGƒbƒNƒXüŽÊ^
@@@@@@- ‚»‚Ì‘¼
@@2D”sŒŒÇ‚É‚æ‚é‹}«ŒÄ‹z‹‡”—ÇŒóŒQiARDSj‚ɑ΂·‚élHŒÄ‹zŠÇ—
@@@2.1 lHŒÄ‹z‚ÌŠJŽnŠî€
@@@2.2 Š·‹CðŒ‚̐ݒè
@@@2.3 Š·‹C—lŽ®
@@@2.4 ‚»‚Ì‘¼‚ÌŠÇ—@
@@3D—p‚¢‚ç‚ê‚郂ƒjƒ^ƒŠƒ“ƒO‘•’uAŒŸ¸
@@@3.1 ŒŒ‰t¶‰»ŠwŒŸ¸
@@@3.2 •aŒ´‘ÌŒŸõ
@@@@3.2.1 ŒŒ‰t”|—{
@@@@3.2.2 •â•f’f
@@@@@@- ŒŒ´Šw“IŒŸ¸
@@@@@@- ƒvƒƒJƒ‹ƒVƒgƒjƒ“
@@@@@@- ”’ŒŒ‹…’†×‹ÛŠjŽ_“¯’茟¸
@@@3.3 ”sŒŒ«ƒVƒ‡ƒbƒN‚É‚¨‚¯‚éDIC
@@@3.4 “®–¬ŒŒ‰tƒKƒX•ªÍ
@@@3.5 “®–¬ŒŒŽ_‘f–O˜a“x
@@@@3.5.1 “®–¬ŒŒŽ_‘f–O˜a“xiarterial oxygen saturationj
@@@@3.5.2 Œo”ç“I“®–¬ŒŒŽ_‘f–O˜a“xiSpO2j
@@4Dƒ‚ƒjƒ^ƒŠƒ“ƒO‹ZpE‘•’uŠJ”­‚ւ̃j[ƒY
@@@4.1 ŒŒ‰t¶‰»ŠwŒŸ¸
@@@4.2 Ž_‘f–O˜a“x‚Ì”ñŠÏŒŒ“I‚ȃ‚ƒjƒ^ƒŠƒ“ƒO‹Zp

@m‚QnS”ƒ‚ƒjƒ^ƒŠƒ“ƒO‹ZpE‘•’u‚ÌŠJ”­
@@1DS”•Ï“®
@@@1.1 S””‚ƐS”•Ï“®
@@@1.2 S”•Ï“®‚ÌŽü”g”¬•ª‚ÆŽ©—¥_ŒoŠˆ“®‚Æ‚ÌŠÖŒW
@@@1.3 S”•Ï“®‰ðÍ‚ÌŽí—Þ
@@@1.4 S”•Ï“®‚ð—˜—p‚µ‚½”sŒŒÇ”­Ç‘Šú”­Œ©‚ÌŽŽ‚Ý
@@2DˆÙíS”‚̏œ‹Ž‚ðŠÜ‚ß‚½S”•Ï“®‰ðÍ
@@@2.1 S“d}‚©‚çS”ŠÔŠu—ñ‚Ö
@@@2.2 ˆÙíS”‚̏œ‹Ž
@@@2.3 ƒgƒŒƒ“ƒhœ‹ŽC•âŠÔCŽü”g”—̈æ‰ðÍ
@@3DS”•Ï“®‚Æ”sŒŒÇ”­Ç‚ÌŠÖ˜A«
@@@3.1 S”•Ï“®‚Æ”sŒŒÇ”­Ç‚ÌŠÖŒW‚Ì’²¸
@@@3.2 S”•Ï“®ƒ‚ƒjƒ^C”sŒŒÇ”­ÇŒŸoŠí‚ÌŽŽì

‘æ‚UßF ˆã—Ë@ŠíEˆã—Íޗ¿‚ÌŠJ”­“®ŒüEŽÀ—p‰»‚̎育‚½‚¦‚ÆŽg‚í‚È‚­‚È‚é‚Å‚ ‚낤–òÜE»•iEŽ¡—Ö@

@m‚PnŽD–yˆã‰È‘åŠw•‘®•a‰@‚É‚¨‚¯‚é”sŒŒÇ‚ÌŒŒ‰tò‰»Ž¡—Â̌»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1D”sŒŒÇ«ƒVƒ‡ƒbƒN‚ÌŽ¡—Ã
@@2D”sŒŒÇ«ƒVƒ‡ƒbƒN‚̐¶‘Ì”½‰ž
@@3D”sŒŒÇ«ƒVƒ‡ƒbƒN‚ɑ΂·‚錌‰tò‰»—Ö@
@@@3.1 zŠÂ“®‘Ô‚Ì‘Šú‰ü‘P
@@@@3.1.1 PMX]DHP‚Ì“K‰žŠî€
@@@@3.1.2 Šú‘Ò‚³‚ê‚éPMX\ DHP‚ÌŽ¡—ÃŒø‰Ê
@@@@3.1.3 PMX\DHP‚ÌŽ{sŽžŠÔ
@@@@3.1.4 ”sŒŒÇ«ƒVƒ‡ƒbƒN‚ɑ΂·‚éPMX]DHP‚Ì—LŒø‹@˜
@@@3.2 ‘ŸŠí•â•

@m‚Qn“ú–{ˆã‰È‘åŠw•‘ ¬™•a‰@‚É‚¨‚¯‚é”sŒŒÇ‚ÌŒŒ‰tò‰»Ž¡—Â̌»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1. ’è‹`
@@2. Œ´ˆö
@@3. ”­Ç‹@˜
@@4. Ž¡—Ã
@@5. “–‰@‚É‚¨‚¯‚éƒGƒ“ƒhƒgƒLƒVƒ“‹z’…—Ö@‚ÌŒ»ó@@@@
@@6. ¡Œã‚ÌŽ¡—Â̗\‘ª
@@@6.1 ˆâ“`Žq‘gŠ·‚¦Œ^ƒgƒƒ“ƒ{ƒ‚ƒfƒ…ƒŠƒ“
@@@6.2 ƒTƒCƒgƒJƒCƒ“œ‹Ž‚ÌŽŽs
@@@@6.2.1 high-volume HF(HVHF)
@@@@6.2.2 AN69 hemofilter
@@@@6.2.3 Super high-flux hemofilter
@@@@6.2.4 CTR-001
@@@@6.2.5 CYT-860
@@@@6.2.6 HMGB1‹z’…ƒJƒ‰ƒ€

@m‚Rn‘åã‘åŠwˆãŠw•”•‘®•a‰@‚É‚¨‚¯‚é”sŒŒÇ‚ÌŒŒ‰tò‰»Ž¡—Â̌»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1DŒŒ‰tò‰»A“§Í—Ö@‚ÌŽÀŽ{‚â”»’fŠî€‚ɂ‚¢‚Ä
@@@1.1 ‘åã‘åŠwˆãŠw•”•‘®•a‰@‚É‚¨‚¯‚錌‰tò‰»Ž¡—Â̌»ó
@@@1.2 “–ƒZƒ“ƒ^[‚É‚¨‚¯‚錌‰tò‰»Ž¡—Â̓±“üŠî€‚Ɖۑè
@@2Dˆã—Íޗ¿Aˆã—Ñ•’u‚ÌŒ¤‹†ŠJ”­‚Ì“®Œü‚ÆŽ¡—Â̕ω»—\‘ª

@m‚SnàՋ¦ˆã‰È‘åŠw‰z’J•a‰@‚É‚¨‚¯‚é”sŒŒÇŽ¡—Â̌»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1D‘ΏہE•û–@
@@2DŒ‹‰Ê
@@3DlŽ@
@@4DŒ‹˜_


Ÿ ‘æ‚TÍF”sŒŒÇ‚É‚¨‚¯‚é–òÜŠJ”­E—Տ°ŽŽŒ±‚ÌŽÀ‘H `—LŒø«EˆÀ‘S«‚ÌŽ¦‚µ•û` @ 

‘æ‚PßF Ž¡—ÖòŠJ”­‚É‚¨‚¯‚é“Š—^–@E—p–@—p—ʂ̐ݒè

@m‚Pn”sŒŒÇŽ¡—Âŗp‚¢‚ç‚ê‚銴õÇŽ¡—Öò‚ÌPK-PD‰ðÍ‚Æ“Š—^ÝŒv
@@1DPK-PD—˜_‚ÉŠî‚­Š´õÇŽ¡—Öò‚Ì•ª—Þ
@@@1.1 Cmax/MICƒ^ƒCƒv
@@@1.2 AUC/MICƒ^ƒCƒv
@@@1.3 “T„MICitime above MICjƒ^ƒCƒv
@@2DPK-PD—˜_‚ÉŠî‚¢‚½ŠeŽíŠ´õÇŽ¡—Öò‚Ì“Š—^ÝŒv
@@@2.1 Cmax/MICƒ^ƒCƒv
@@@@2.1.1 ƒAƒ~ƒmƒOƒŠƒRƒVƒhŒn–ò
@@@@2.1.2 ƒAƒ€ƒzƒeƒŠƒVƒ“B
@@@2.2 AUC/MICƒ^ƒCƒv
@@@@2.2.1 ƒLƒmƒƒ“Œn–ò
@@@@2.2.2 ƒOƒŠƒRƒyƒvƒ`ƒhŒn–ò
@@@@2.2.3 ƒAƒ][ƒ‹ŒnR^–ò@
@@@2.3 “T„MICƒ^ƒCƒv
@@@@2.3.1 ƒÀ]ƒ‰ƒNƒ^ƒ€Œn–ò
@@3DPK-PD—˜_‚É‚¨‚¯‚é‘ϐ«‹ÛoŒ»‚ÉŠÖ‚·‚él‚¦•û

@m‚Qn—p–@—p—ʂ̐ݒè—á
@@1D‘æI‘ŠŽŽŒ±
@@@1.1 ‰‰ñ“Š—^—ʂ̐ݒè
@@@1.2 NOAEL‚ð—p‚¢‚½MRSD‚̐ݒè—á
@@@1.3 NOAEL‚ ‚é‚¢‚ÍMABEL‚ð—p‚¢‚½‚Æ‚«‚ÌMRSD‚̈Ⴂ
@@2D‘æII‘ŠŽŽŒ±
@@@2.1 ŒãŠú‘æII‘ŠŽŽŒ±—á
@@3D‘æIII‘ŠŽŽŒ±

‘æ‚QßF Ž¡Œ±ŽÀŽ{‚É‚¨‚¯‚é”팱ŽÒ‘I’èEÇ—áƒGƒ“ƒgƒŠ[‚Ì—¯ˆÓ“_

@m‚Pn”sŒŒÇ‚ÌŽ¡Œ±‚É‚¨‚¯‚éƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg‚ÌŽÀŽ{‚Ɖۑè
@@1DƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg‚Æ‚Í
@@@1.1 Ž¡Œ±‚É‚¨‚¯‚é”팱ŽÒ‚Ö‚Ìà–¾
@@@1.2 “–‰@‚É‚¨‚¯‚鎡Œ±‚ł̔팱ŽÒ‚Ö‚Ìà–¾
@@2D”sŒŒÇ‚ÌŽ¡Œ±‚É‚¨‚¯‚éƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg‚ÌŽ–—á
@@@2.1 ”wŒi
@@@2.2 “¯ˆÓà–¾‚ÌŽÀŽ{
@@@2.3 ‘ã‘øŽÒi‰Æ‘°j‚ɑ΂·‚éƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg
@@3D”sŒŒÇ‚ÌŽ¡Œ±‚É‚¨‚¯‚éƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg‚̉ۑè
@@@3.1 CRC•sÝŽž‚̃Cƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg
@@@3.2 ‰Æ‘°(‘ã‘øŽÒ)‚͏\•ª‚É—‰ð‚Å‚«‚邾‚¯‚̏î•ñ‚ÆŽžŠÔ‚𓾂½‚Ì‚©
@@4D‰Û‘è‰ðŒˆ‚Ì‚½‚ß‚Ì’ñˆÄ
@@@4.1 CRC•sÝ‚ł̃Cƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg
@@@4.2 ”»’f‚·‚邽‚߂̏\•ª‚ÈŽžŠÔ‚Əî•ñ

@m‚Qn”sŒŒÇŽ¡Œ±‚É‚¨‚¯‚é”팱ŽÒ‘I’莖—á
@@1D‘I‘ðŠî€
@@2DœŠOŠî€
@@@2.1 ”팱–ò‚Ì—LŒø«‹y‚шÀ‘S«•]‰¿‚ɉe‹¿‚·‚é“ÁˆÙ“IŽ–€
@@@2.2 Š³ŽÒ‚̈À‘S«‚ÉŠÖ‚í‚éˆê”Ê“I”z—¶
@@@2.3 ‚»‚Ì‘¼

‘æ‚RßF ”sŒŒÇ‚ÌŽ¡Œ±ƒfƒUƒCƒ“EƒGƒ“ƒhƒ|ƒCƒ“ƒgÝ’è

@m‚Pnˆã—Ë@ŠÖ‚©‚猩‚½Ž¡Œ±ƒfƒUƒCƒ“‚̃|ƒCƒ“ƒg
@@1DŽ¡Œ±ƒfƒUƒCƒ“
@@@1.1 ƒGƒ“ƒhƒ|ƒCƒ“ƒg‚̐ݒè
@@@1.2 ƒTƒ“ƒvƒ‹ƒTƒCƒY‚̐ݒè
@@@1.3 ƒ‰ƒ“ƒ_ƒ€‰»ŽŽŒ±
@@@1.4 ƒRƒ“ƒsƒ…[ƒ^[‚É‚æ‚é–³ìˆ×Š„‚è•t‚¯
@@@1.5 “ñd–ÓŒŸ–@
@@2D¡ŒãŠú‘Ò‚³‚ê‚鎡Œ±ƒfƒUƒCƒ“
@@@2.1 Å‹ßs‚í‚ꂽŽ¡Œ±
@@@2.2 ¡ŒãŠú‘Ò‚³‚ê‚鎡Œ±ƒfƒUƒCƒ“

@m‚Qn“ŒvŠw‚©‚ç‚Ý‚½—Տ°ŽŽŒ±ƒfƒUƒCƒ“‚̃|ƒCƒ“ƒg
@@1D•]‰¿ŽÚ“x‚̐ݒè
@@@1.1 •]‰¿ŽÚ“x‚Ì’è‹`
@@@1.2 ”sŒŒÇ—Տ°ŽŽŒ±‚É‚¨‚¯‚é•]‰¿ŽÚ“x
@@@1.3 •]‰¿ŽÚ“x‚Æ“Œv‰ðÍ
@@@1.4 •]‰¿ŽÚ“x‚ƃTƒ“ƒvƒ‹”
@@2D“KŠi‹K€
@@@2.1 “KŠiŠî€‚Æ‚Í
@@@2.2 “KŠi‹K€‚Æ—LŒø«‚Ì•]‰¿
@@3D—LŒø«‚ƈÀ‘S«‚Ì•]‰¿•û–@i“Œv‰ðÍŽè–@j
@@@3.1 „’è‚ÉŠÖ‚·‚é—¯ˆÓ“_
@@@@3.1.1 ˜A‘±ƒf[ƒ^‚Ì•ª•z‚Ì“Á’¥‚¯
@@@@3.1.2 2’lƒf[ƒ^‚Ì•ª•z‚Ì“Á’¥‚¯
@@@@3.1.3 Time to Eventƒf[ƒ^‚Ì•ª•z‚Ì“Á’¥‚¯
@@@3.2@ŒŸ’è‚ÉŠÖ‚·‚é—¯ˆÓ“_
@@@@3.2.1 2ŒQ‚ÌŠ„‡‚̍·‚ÌŒŸ’è
@@@@3.2.2 2ŒQ‚̘A‘±ƒf[ƒ^‚Ì•ª•z‚̍·‚ÌŒŸ’è
@@@@3.2.3 Time-to-Event data‚ÉŠî‚­¶‘¶—¦‹Èü‚È‚Ç‚Ì”äŠr
@@4DƒTƒ“ƒvƒ‹”‚̐„’è
@@@4.1 Ç—ᐔÝ’è‚Ì•K—v«
@@@4.2 ƒTƒ“ƒvƒ‹”ŽZo‚Ì‚½‚ß‚ÌŽÀ‘H“IŽè‡
@@@@4.2.1 •]‰¿ŽÚ“x‚̐«Ž¿‚ðl—¶‚µ‚Ä“Œv‰ðÍŽè–@iŽ¡—ÃŒø‰Ê”»’èA—LŠQŽ–ÛŒŸo‚ÌŽè–@j
@@@@4.2.2 “Œv‰ðÍŽè–@‚̃Tƒ“ƒvƒ‹”‚ðŽZo‚·‚邽‚ß‚ÌŒöŽ®‚Ü‚½‚̓Vƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“ƒvƒƒOƒ‰ƒ€‚ðŒ©‚Â‚¯‚é
@@@@4.2.3 ŒöŽ®‚Ü‚½‚̓Vƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚ðŽg—p‚·‚éÛ‚É•K—v‚Æ‚È‚é’l‚ð“üŽè‚·‚é
@@@@4.2.4 ŒöŽ®‚âƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“ƒvƒƒOƒ‰ƒ€‚É“¾‚ç‚ꂽ’l‚ð‘ã“ü‚µ‚ďǗᐔ‚ðŽZo‚·‚é
@@@@4.2.5 ŽZo‚³‚ꂽÇ—ᐔ‚ªŽÀÛ‚̗Տ°Œ¤‹†‚ŏWÏ‰Â”\‚©ŒŸ“¢‚·‚é
@@5DƒTƒ“ƒvƒ‹”ŽZo‚Ì—ái2ŒQ‚Ì—LŒø—¦‚Ì—LˆÓ·ŒŸ’è‚̏ꍇj

@m‚Rn”A˜HŒ´«”sŒŒÇ‚ÌŽ¡Œ±ƒfƒUƒCƒ“‚ÌŽÀ‘HŽ–—á
@@1D”A˜HŒ´«”sŒŒÇ‚Ì’è‹`‚ÆŽ¡Œ±ƒfƒUƒCƒ“‚ðl‚¦‚éã‚Å‚Ì–â‘è“_
@@@1.1 ’è‹`
@@@1.2 –â‘è“_
@@2DŽ–—á’ñŽ¦FuŽÀŒ±Œv‰æ‘v
@@@2.1 ‘Ώێ¾Š³
@@@@2.1.1 ‘I‘ðŠî€
@@@@2.1.2 ’E—ŽŠî€
@@@@2.1.3 œŠOŠî€
@@@2.2 ŽŽŒ±•û–@
@@@@2.2.1 “Š—^•û–@‚¨‚æ‚Ñ“Š—^“ú”
@@@@2.2.2 •¹—p–òÜ
@@@@2.2.3 ŠÏŽ@€–Ú
@@@@@2.2.3.1 Š³ŽÒ”wŒi
@@@@@2.2.3.2 —Տ°Œo‰ß
@@@@@2.2.3.3 ×‹ÛŠw“IŒŸ¸
@@@@@2.2.3.4 —Տ°ŒŸ¸
@@@2.3 •]‰¿•û–@
@@@@2.3.1 Œø‰Ê”»’è‚ÌŽžŠú
@@@@2.3.2 —Տ°Œø‰Ê
@@@@@2.3.2.1 ”sŒŒÇ
@@@@2.3.3 ×‹ÛŠw“IŒø‰Ê
@@@@@2.3.3.1 ”sŒŒÇ
@@@@@2.3.3.2 t᱐t‰ŠA‹}«×‹Û«‘O—§‘B‰ŠA‹}«¸‘ƒã‘̉Š
@@@@2.3.4 ‹ÛŽí•Ê×‹ÛŠw“IŒø‰Ê
@@@@@@@i”sŒŒÇAt᱐t‰ŠA‹}«×‹Û«‘O—§‘B‰ŠA‹}«¸‘ƒã‘̉Šj
@@@@2.3.5 —LŒø«‚Ì•]‰¿
@@@@2.3.6 —LŠQŽ–Û
@@@2.4 “Œv‰ðÍ
@@@@2.4.1 —LŒø«‰ðÍ‘ΏۏW’c
@@@@2.4.2 ˆÀ‘S«‰ðÍ‘ΏۏW’c
@@@2.5 ‚»‚Ì‘¼
@@3D‚»‚Ì‘¼A•K—v‚ȏ‘—Þ
@@4D‚Ü‚Æ‚ß

@m‚SnŽ¡Œ±ƒfƒUƒCƒ“‚ÌŽÀ‘HŽ–—á
@@1DVasopressin and Septic Shock Trial (VASST)
@@@1.1 ”sŒŒÇ«ƒVƒ‡ƒbƒN‚ÆŒŒŠÇŽûk–ò
@@@1.2 ƒoƒ\ƒvƒŒƒbƒVƒ“‚̍ì—p‚ÆŽ¡—Öò‚Æ‚µ‚Ä‚Ì”wŒi
@@@1.3 VASSTˆÈ‘O‚Ì”sŒŒÇ«ƒVƒ‡ƒbƒN‚ɑ΂·‚éƒoƒ\ƒvƒŒƒbƒVƒ“‚ÉŠÖ‚·‚錤‹†
@@@1.4 VASST‚ÌŒ¤‹†ƒfƒUƒCƒ“‚ƃGƒ“ƒhƒ|ƒCƒ“ƒg
@@2DProspective Recombinant Human Activated Protein C World- wide Evaluation in Severe Sepsis and Septic Shock (PROWESS-SHOCK)
@@@2.1 Approved specific drug‚©‚çŽsê“P‘Þ‚ÖŽŠ‚Á‚½recombinant human activated protein C (rhAPC)
@@@2.2 PROWESS-SHOCKˆÈ‘O‚ÌrhAPC‚ÉŠÖ‚·‚錤‹†
@@@2.3 PROWESS-SHOCK‚ÌŒ¤‹†ƒfƒUƒCƒ“‚ƃGƒ“ƒhƒ|ƒCƒ“ƒg
@@3DdÇ”sŒŒÇ‚ɑ΂·‚郉ƒNƒgƒtƒFƒŠƒ“‚Ìphase 2 trial

‘æ‚SßF ”sŒŒÇ‚̗Տ°ŽŽŒ±‚É‚¨‚¯‚éƒvƒƒgƒR[ƒ‹ì¬‚̃|ƒCƒ“ƒg

@m‚PnŽ¡Œ±ˆãŽt‚ÌŽ‹“_‚©‚ç‚Ý‚½ƒvƒƒgƒR[ƒ‹ì¬‚̃|ƒCƒ“ƒg
@@1DŽ¡Œ±‚Ì—¬‚ê
@@@1.1 ‘æ‚P‘ŠŽŽŒ±
@@@1.2 ‘æ‚Q‘ŠŽŽŒ±
@@@1.3 ‘æ‚R‘ŠŽŽŒ±
@@@1.4 ‘æ‚S‘ŠŽŽŒ±
@@2DƒvƒƒgƒR[ƒ‹ì¬‚̃|ƒCƒ“ƒg
@@@2.1 ƒvƒƒgƒR[ƒ‹ì¬‚ÌŽÀÛ
@@@2.2 ”sŒŒÇ‚ÉŠÖ‚·‚é—Տ°ŽŽŒ±‰^—p‚ÉŠÖ‚·‚钍ˆÓ“_

@m‚QnŽ¡Œ±ˆË—ŠŽÒ‚ÌŽ‹“_‚©‚ç‚Ý‚½ƒvƒƒgƒR[ƒ‹ì¬‚̃|ƒCƒ“ƒg
@@1D‘æ1‘Š‹y‚Ñ‘æ2‘ŠŽŽŒ±‚Å—¯ˆÓ‚·‚ׂ«Žå‚ȃ|ƒCƒ“ƒg
@@@1.1 ‘æ1‘ŠŽŽŒ±
@@@1.2 ‘æ2‘ŠŽŽŒ±
@@2D‘æ3‘ŠŽŽŒ±‚Å—¯ˆÓ‚·‚ׂ«Žå‚ȃ|ƒCƒ“ƒg
@@@2.1 ’è‹`
@@@2.2 –Ú•WÇ—ᐔ
@@@2.3 f’fŠî€
@@@2.4 ‘I‘ðEœŠOŠî€
@@@@2.4.1 ‘I‘ðŠî€
@@@@2.4.2 œŠOŠî€
@@@2.5 —Տ°ŽŽŒ±•û–@
@@@@2.5.1 “o˜^•û–@
@@@@2.5.2 ŒŸ¸
@@@@2.5.3 “Š—^—ʁE“Š—^ŽžŠúE“Š—^ŠúŠÔ
@@@@2.5.4 •¹—p–òE•¹—p—Ö@
@@@@2.5.5 —LŒø«•]‰¿
@@@@@2.5.5.1 —Տ°Œø‰Ê
@@@@@2.5.5.2 ×‹ÛŠw“IŒø‰Ê
@@@2.6 ’†’fE’†Ž~Šî€

@m‚Rn—Տ°ŒŸ¸‚ÌŽ‹“_‚©‚猩‚½ƒvƒƒgƒR[ƒ‹ì¬EŽ¡Œ±ŽÀ‘H‚̃|ƒCƒ“ƒg
@@1D”sŒŒÇ‚ƗՏ°ŒŸ¸
@@@1.1 ”sŒŒÇ‚Ì’è‹`‚ÆŠÖ˜A‚·‚é—Տ°ŒŸ¸
@@@1.2 —Տ°ŽŽŒ±‚É‚¨‚¯‚錟¸‚ÌŽÀŽ{‹@ŠÖ
@@2D“ú–{”Å”sŒŒÇf—ÃKƒCƒhƒ‰ƒCƒ“‚ƗՏ°ŒŸ¸
@@@2.1 ŒŒ‰tŠw“IŒŸ¸
@@@@2.1.1 ŒŒ‹…”‚Æ”’ŒŒ‹…•ª‰æ
@@@@2.1.2 ‹ÃŒÅ‚¨‚æ‚ѐü—nŠÖ˜AŒŸ¸
@@@2.2 ¶‰»Šw“IŒŸ¸
@@@@2.2.1 ŒŒ“œ
@@@@2.2.2 “ûŽ_
@@@@2.2.3 CrAT-Bil
@@@@2.2.4 ¶‰»ŠwŒŸ¸‚É‚¨‚¯‚é‰@“àŒŸ¸‚Ɖ@ŠOŒŸ¸
@@@@2.2.5 ¸“xŠÇ—‚Æ•W€‰»
@@@2.3 ƒoƒCƒIƒ}[ƒJ[
@@@@2.3.1 CRPAPCT
@@@@2.3.2 ƒGƒ“ƒhƒgƒLƒVƒ“
@@@@2.3.3 IL-6A‰Â—n«CD14 ƒTƒuƒ^ƒCƒv
@@@2.4 ×‹ÛŠw“IŒŸ¸
@@@@2.4.1 ×‹ÛŒŸ¸‚É‚¨‚¯‚錟‘̍̎æ
@@@@2.4.2 ƒOƒ‰ƒ€õF
@@@@2.4.3 ŒŒ‰t”|—{
@@@@2.4.4 ŒŸ¸Œ‹‰Ê•ñ
@@@@2.4.5 ‚»‚Ì‘¼i’²®‚Ȃǁj
@@@2.5 ŒÄ‹zŠíŠÖ˜AŒŸ¸
@@@@2.5.1 ŒŒ‰tƒKƒX
@@@@2.5.2 ƒpƒ‹ƒXƒIƒLƒVƒ[ƒ^[‚É‚æ‚é Ž_‘f–O˜a“x(SpO2)
@@3D—Տ°ŽŽŒ±‚ðs‚¤‚½‚߂̑̐§
@@@3.1 ŠO•”ˆÏ‘õŒŸ¸‚É‚¨‚¯‚錟¸ŽŽ—¿‚̉ñŽûi—A‘—j
@@@3.2 ŒŸ¸Žº‚̑̐§‚ƑΉž
@@@@3.2.1 ŒŸ¸Žº‚Ì24ŽžŠÔ‘̐§
@@@@3.2.2 ŒŸ¸Žº‚̑Ήž
@@@@@@- —Տ°ŽŽŒ±ŽÀŽ{‚̉”ۂ̌©‹É‚ß
@@@@@@- —Տ°ŽŽŒ±ŽÀŽ{‚ÉŒü‚¯‚Ä‚Ì‘o•ûŒü«‚Ì’²®‚ÌŽÀŽ{
@@@3.3 ‹L˜^‚Ì•ÛŠÇ

‘æ‚TßF ”sŒŒÇ‚ÌŽ¡Œ±‚É‚¨‚¯‚é•âž‚Ì‹àŠzE”͈͂̐ݒè
@1D•âžÓ”C‚Æ”…žÓ”C
@2DGCPÈ—ß‚â—Ï—Žwj‚ª‹‚ß‚Ä‚¢‚邱‚Æ
@3D‰¢•Ä‚É‚¨‚¯‚é•âžE”…žŽ–î
@4Dˆã–@Œ¤ƒKƒCƒhƒ‰ƒCƒ“‚ɂ‚¢‚Ä
@@4.1 •½¬11”N”­•\‚̈ã–@Œ¤•âž‚̃KƒCƒhƒ‰ƒCƒ“iŒ»sƒKƒCƒhƒ‰ƒCƒ“j‚ɂ‚¢‚Ä
@@4.2 •½¬21”Nu”팱ŽÒ‚ÌŒ’N”íŠQ•âž‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“v‚ÌŠT—v‚Æ‚»‚Ì–â‘è“_
@5D‚i•‚sƒKƒCƒhƒ‰ƒCƒ“‚ɂ‚¢‚Ä
@@5.1 ‚i•‚sƒKƒCƒhƒ‰ƒCƒ“‚ÌŠT—v‚͈ȉº‚Ì’Ê‚è‚Å‚ ‚éB
@@@5.1.1 ”ñŠ³ŽÒ‘ΏێŽŒ±‹y‚уƒNƒ`ƒ“ŽŽŒ±
@@@5.1.2 Š³ŽÒ‘ΏێŽŒ±
@@5.2 –ò•¨Ž¡—ʳŽÒ•s–ž‘«“xiƒAƒ“ƒƒbƒgƒƒfƒBƒJƒ‹ƒj[ƒYj‚ɂ‚¢‚Ä
@@5.3 ˆâŽ¸—˜‰v‚ÌŒvŽZiƒAƒ“ƒƒbƒgƒƒfƒBƒJƒ‹ƒj[ƒYŒ¸Šzj‚ɂ‚¢‚Ä | ”sŒŒÇ‚ÌŽ¡Œ±
@6D•âžE”…ž‘Ήž‚ÌŽÀ–±
@@6.1 Œ’N”íŠQ”­¶Žž‚̏‰Šú‘Ήž
@@6.2 –¢’m‚©Šù’m‚©‚Ì”»’è‚âˆö‰ÊŠÖŒW‚Ì”»’è
@@6.3 Œ’N”íŠQ”»’èˆÏˆõ‰ï‚̐ݒu‚Ɖ^—pã‚̃|ƒCƒ“ƒg
@@6.4 Ž¡—Ôï‚ōςޏꍇ‚̑Ήž
@@6.5 •âž‹à‚ÌŽx•¥‚¢‚ª–â‘è‚Æ‚È‚éê‡‚̑Ήž
@@6.6 •s•ž‚ª‚ ‚Á‚½ê‡‚̔팱ŽÒ‚ւ̑Ήž
@@6.7 ˆã—Ë@ŠÖ‚âŽó‘õ‹@ŠÖiCROESMOj‚Æ‚ÌŠÖŒW
@7D•âž‹y‚Ñ”…žÓ–±‚Ì—šs‚ƕ⏞Ó”C•ÛŒ¯
@@7.1 VŽ¡Œ±•ÛŒ¯E—Տ°Œ¤‹†•âž•ÛŒ¯‚ɂ‚¢‚Ä
@@7.2 iPS×–E‚ðŽg‚Á‚½—Տ°Œ¤‹†‚ÉŒW‚é•âžÓ”C•ÛŒ¯‚Å‹c˜_‚µ‚½‚±‚Æ
@@7.3 ‹ÆŠE‰¡’f“I‚ȃtƒ@ƒ‹ƒ}ƒv[ƒ‹‚Ì’ñˆÄ

‘æ‚UßF ”sŒŒÇ‚ÉŠÖ‚·‚é—LŠQŽ–ÛEˆÀ‘S«î•ñ‚ÌŽûW‚ÆŽs”ÌŒã‹Æ–±‚ÌŽÀ‘H
@1Dˆã–ò•i‚Ì—LŠQŽ–Û‚Æ‚Í
@@1.1 —LŠQŽ–Û•]‰¿‚É‚¨‚¯‚éŽå—v3—v‘f
@@1.2 ˆö‰ÊŠÖŒW
@@@[‘Š“–ˆö‰ÊŠÖŒW•]‰¿‚̊]
@@@[ŠÖ˜A«”í‹^—v‘f]
@@@[Ž¡Œ±‚É‚¨‚¯‚éUS‚ÌŠÖ˜A«‚̊]
@@@[Ž¡Œ±‚É‚¨‚¯‚éEU‚ÌŠÖ˜A«‚̊]
@@@[ŠÖ˜A«•]‰¿]
@2Dd“Đ«
@@@[d“Đ«‚̊]
@@@[US‚̏d“Đ«‚̊]
@@@[EU‚̏d“Đ«‚̊]
@3D—\‘ª«•]‰¿
@@@[US‚̐ê–å—pŒê‚Ì’è‹`]
@@@[US‚̘A–M–@‹K§u—\‘ª‚Å‚«‚È‚¢v‚ɂ‚¢‚ẲðŽß]
@4D”sŒŒÇ‚Ì’è‹`
@5D”sŒŒÇ‚̏dÇ“x•ª—Þ
@6DŽ¡Œ±–ò“Š—^’†‚¨‚¯‚é—LŠQŽ–Û‚ÌŽûW
@7D”sŒŒÇ‚ÉŠÖ‚·‚é—LŠQŽ–Û


Ÿ ‘æ‚UÍF”sŒŒÇŽ¡—Öò‚ÌŽsê—\‘ª‚ÆŽ–‹Æí—ª @ 
‘æ‚PßF ”sŒŒÇŽ¡—Â̎sê“®ŒüEƒAƒ“ƒƒbƒgƒj[ƒY‚ÆŠ³ŽÒ”E”„ã—\‘ª
@1D”sŒŒÇŽ¡—ÃŽsê“®Œü
@@1.1 ”sŒŒÇŽ¡—ÃŽsê‚Ì’è‹`
@@1.2 ”sŒŒÇŠ³ŽÒ”‚Ì“®Œü
@2DƒAƒ“ƒƒbƒgƒj[ƒY
@@2.1 ƒAƒ“ƒƒbƒgƒj[ƒY‚Ì’è‹`
@@2.2 ’萫“I‚È’Tõ‚Ì‚â‚è•û
@@2.3 ’è—Ê“I‚È’Tõ‚Ì‚â‚è•û
@@2.4 ‰^—pã‚Ì—¯ˆÓ“_
@@2.5 ”sŒŒÇŽ¡—Öò‚É‚¨‚¯‚éƒAƒ“ƒƒbƒgƒj[ƒY‚ÌŽ–—áÐ‰î@
@3D”„ã—\‘ª
@@3.1 ”„ã—\‘ª‚ɑ΂·‚éˆê”Ê“I‚ÈŒ©‰ð
@@3.2 ‹ï‘Ì“I‚ȃAƒvƒ[ƒ`
@@3.3 ”sŒŒÇŽ¡—Öò‚ÉŠÖ‚·‚éŽsê‘S‘Ì—\‘ª
@@3.4 ”sŒŒÇŽ¡—Öò‚̐»•i”„ã—\‘ª‚Ì’ˆÓ“_
@@@3.4.1 “–ŠYŽ¡—Öò‚ªA‚Ç‚Ì•a‘ԂɁAŒø‰Ê‚ð”­‚·‚é‚©‚ð”cˆ¬‚µ‚½ŒãA
@@@@@@@‚ǂ̃†ƒjƒo[ƒX‚̈ãŽtA‘¦‚¿A‚ǂ̐f—Ã‰È‚à‚µ‚­‚͂ǂ̐ê–å‰È‚ªŽå‚½‚郆[ƒU[‚ƂȂ肤‚é‚Ì‚©H
@@@3.4.2 ˆãŽt‚Ì‚Ç‚ê‚­‚ç‚¢‚ªAˆ•û‚ðŒŸ“¢‚µ‚Ä‚à‚ç‚¢‚½‚¢Š³ŽÒƒ^ƒCƒv‚𐳂µ‚­”FŽ¯‚µ‚Ä‚¢‚é‚©H
@@@3.4.3 ˆãŽt‚ª“–ŠYŽ¾Š³—̈æ\‚±‚̏ꍇ‚Í”sŒŒÇŽ¡—Á\‚É‚¨‚¢‚āA
@@@@@@@ ‚Ç‚¤‚¢‚¤ƒ|ƒCƒ“ƒg‚ðd—vŽ‹‚µ‚āA‚ǂ̂悤‚Ȑ»•iƒvƒƒtƒ@ƒCƒ‹‚É”½‰ž‚·‚é‚Ì‚©H
@@@3.4.4 ƒvƒ‰ƒCƒ}ƒŠ[ƒŠƒT[ƒ`Œ‹‰Ê‚̉ߑå•]‰¿‚ð‚ǂ̂悤‚É’²®‚·‚é‚©H
@@@3.4.5 ‹£‡•i‚ÌŽQ“üƒ^ƒCƒ~ƒ“ƒO‚ð‚Ç‚¤‚Ý‚é‚©H
@@@3.4.6 “K‰žÇ’ljÁ‚̏ꍇ‚ɁAŠùŽg—p‚Ì“K—pŠOŽg—p‚ð‚Ç‚¤Œ©Ï‚à‚é‚©H

‘æ‚QßF ”sŒŒÇŽ¡—ÂɊւ·‚éˆã—ÃŒoÏ•]‰¿
@1D”sŒŒÇ‚ÌŽ¾•a•‰’S
@2D”sŒŒÇ‚Ì”ï—pŒø‰Ê•ªÍ
@@2.1 ƒ~ƒJƒtƒ@ƒ“ƒMƒ“iƒtƒ@ƒ“ƒK[ƒhj‚Ì”ï—pŒø‰Ê•ªÍ
@@2.2 Drotrecoginalfa (activated)iƒUƒCƒOƒŠƒXj‚Ì”ï—pŒø‰Ê•ªÍ
@@2.3 ƒ‰ƒsƒbƒhPCRƒAƒbƒZƒC‚É‚æ‚éMRSA‚Ì“¯’è‚Ì”ï—pŒø‰Ê•ªÍ
@@2.4 ƒ|ƒŠƒ~ƒLƒVƒ“BŒÅ’艻‘@ˆÛƒJƒ‰ƒ€Žg—p‚Ì”ï—pŒø‰Ê•ªÍ
@3DŒ‹Œê

‘æ‚RßF ”sŒŒÇŽ¡—ÂɊւ·‚é“Á‹–í—ª

@m‚Pn”sŒŒÇŽ¡—ÂɊւ·‚é“Á‹–’²¸‚ÌŽÀ‘H
@@1D“Á‹–’²¸‚Ì•K—v«
@@@1.1 æs‹Zp’²¸iV‹K«’²¸j
@@@1.2 NŠQ–hŽ~’²¸
@@@1.3 –³ŒøŽ‘—¿’²¸
@@2D“Á‹–ŒŸõ‚̃L[
@@@2.1 ƒL[ƒ[ƒhŒŸõ
@@@2.2 “Á‹–•ª—ÞŒŸõ
@@@2.3 ‰»‡•¨ŒŸõ
@@3Dƒf[ƒ^ƒx[ƒX‚Ì‘I‘ð
@@@3.1 ‰»‡•¨ŒŸõ
@@@3.2 ƒyƒvƒ`ƒhŒŸõ
@@@3.3 »Ü‚Ì’²¸
@@@3.4 V‹K—p“r‚Ì’²¸
@@@3.5 ‡Ü‚Ì’²¸

@m‚Qn”sŒŒÇ‚ÉŠÖ˜A‚·‚éˆã—ËZp‚ÌŒ —˜‰»EoŠèí—ª
@@1D“Á‹–”­–¾‚Æ‚µ‚ĕی삳‚ê‚éŒ`
@@@1.1 ”­–¾‚̃JƒeƒSƒŠ[
@@@1.2 ˆã—Ê֘A”­–¾‚Ì“ÁŽê«
@@@1.3 ‰ä‚ª‘‚Å•ÛŒì‚ðŽó‚¯‚邱‚Æ‚ª‚Å‚«‚È‚¢ˆã—Ê֘A”­–¾
@@@@1.3.1 f’f•û–@‹y‚ÑŒŒ‰tò‰»—Ö@
@@@@1.3.2 •a‘Ôƒ‚ƒjƒ^ƒŠƒ“ƒO
@@@1.4 ”ŠO‘‚É‚¨‚¯‚éó‹µ
@@@1.5 •ÛŒì‚ðŽó‚¯‚邽‚ß‚Ì•ûô
@@2D“Á‹–‚ðŽó‚¯‚邽‚ß‚Ì—vŒ
@@3D“Á‹–oŠèí—ª
@@@3.1 oŠèƒ‹[ƒg
@@@3.2 oŠè‚̃^ƒCƒ~ƒ“ƒO‚ÆŽÀØƒf[ƒ^

@m‚Rn”sŒŒÇŽ¡—Öò‚ÉŠÖ‚·‚郉ƒCƒZƒ“ƒXŒðÂEŒ_–ñŽž‚Ì—¯ˆÓ“_
@@1Dƒ‰ƒCƒZƒ“ƒXŒðÂ‚ɉ—‚¯‚é—¯ˆÓ“_
@@@1.1 Territory
@@@1.2 License Fee
@@@@1.2.1 Down paymentA Initial payment
@@@@1.2.2 ƒ}ƒCƒ‹ƒXƒg[ƒ“ƒyƒCƒƒ“ƒg
@@@@1.2.3 ƒƒCƒ„ƒ‹ƒeƒB
@@@@1.2.4 Å‹ß‚̃ƒCƒ„ƒ‹ƒeƒB—¦‚ÌŒXŒü
@@2Dƒ‰ƒCƒZƒ“ƒXŒ_–ñ‚ɉ—‚¯‚éŽå—vð€‚Ì—¯ˆÓ“_
@@@2.1 Grant of License@iŽÀŽ{‹–‘øj
@@@@2.1.1 ê—pŽÀŽ{Œ 
@@@@2.1.2 ’ʏíŽÀŽ{Œ 
@@@@2.1.3 ÄŽÀŽ{Œ iƒTƒuƒ‰ƒCƒZƒ“ƒXj

‘æ‚SßF ”sŒŒÇ‚ÌŽŸ¢‘ãˆã—ËZp‚Ì“®Œü‚ð‚Ó‚Ü‚¦‚½—Տ°‚ÅŽg‚í‚È‚­‚È‚é(‚Å‚ ‚낤)–òÜE»•i—\‘ª
@@@@@@@ `Še—Տ°ˆãŽt‚ªŠ´‚¶‚éˆã—Ãj[ƒY‚⎡—Â̕ω»—\‘ª`

@m‚Pn‹ž“s‘æˆêÔ\Žš•a‰@‚ł̐f’fEŽ¡—Â̌»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1DŒ»Ý‚Ì–òÜEŽ¡—Ö@‚Ì‘I‘ð‚ÌŒ»ó
@@@1.1 f’fEŒŸ¸‚ÌŒ»ó
@@@1.2 –òÜ‚Ì‘I‘ðŠî€‚ƃj[ƒYiR‹Û–òA—AŒŒ—Ö@A‹­S–òAƒXƒeƒƒCƒhAŒŒ‰t»ÜA’ÁÃ–òA’Á’É–òj
@@@@1.2.1 –ƉuƒOƒƒuƒŠƒ“
@@@@1.2.2 ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“III
@@@@1.2.3 ƒXƒeƒƒCƒh
@@2DV–òE‹@ŠíEf’f‹Zp‚ÌŠJ”­‚ªi‚Þ‚ÆŽg‚í‚È‚­‚È‚é‚Å‚ ‚낤»•i‚ƁAV‚½‚ÉŽg—p‹@‰ï‚ª‘‚¦‚»‚¤‚Ȑ»•i
@@@2.1 5”NŒã‚̐f’fEŽ¡—ÁE‹@Ší‚Ì‘I‘ð—\‘ª
@@@@2.1.1 ’†SÃ–¬ˆ³‚ðŽw•W‚Æ‚·‚鏉Šú—A‰t
@@@@2.1.2 ŒoÃ–¬‰h—{
@@@@2.1.3 CRP‘ª’è
@@@2.2 10”NŒã‚̐f’fE–òÜA‹@Ší‚Ì‘I‘ð—\‘ª
@@@@2.1.1 ŒŒ‰t”|—{
@@@@2.1.1 lHŒÄ‹z‚É”º‚¤’ÁÃÜ

@m‚QnŠÖ¼ˆã‰È‘åŠw–‡•û•a‰@‚ł̐f’fEŽ¡—Âƍ¡Œã‚̕ω»—\‘ª
@@1DŒ»Ý‚Ì–òÜEŽ¡—Ö@‚Ì‘I‘ð‚ÌŒ»ó
@@@1.1 f’fEŒŸ¸‚ÌŒ»ó
@@@1.2 –òÜ‚Ì‘I‘ðŠî€‚ƃj[ƒY
@@2D«—ˆ‚Ì”sŒŒÇŽ¡—Âɂ¨‚¯‚鎡—Â̕ω»—\‘ª
@@@2.1 ¡ŒãŽg—p‹@‰ï‚ª‘‚¦‚Ä‚¢‚­‚Å‚ ‚낤–òÜ
@@@2.2 ¡ŒãŽg—p‹@‰ï‚ªŒ¸‚Á‚Ä‚¢‚­‚Å‚ ‚낤–òÜ

@
m‚RnNTT“Œ“ú–{ŠÖ“Œ•a‰@‚ł̐f’fEŽ¡—Â̌»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1. Œ»Ý‚Ì–òÜEŽ¡—Ö@‚Ì‘I‘ð‚ÌŒ»ó
@@@1.1 f’fEŒŸ¸‚ÌŒ»ó
@@@1.2 –òÜ‚Ì‘I‘ðŠî€‚ƃj[ƒY
@@@1.3 ŒŒ‰tò‰»A“§ÍŽ¡—Â̎ÀŽ{‚â”»’fŠî€‚ɂ‚¢‚Ä
@@2. V–òE‹@ŠíEf’f‹Zp‚ÌŠJ”­‚ªi‚ނƁAŽg‚í‚È‚­‚È‚é‚Å‚ ‚낤»•i‚ƁAV‚½‚ÉŽg—p‹@‰ï‚ª‘‚¦‚»‚¤‚Ȑ»•i
@@@2.1 5”NŒã‚̐f’fEŽ¡—ÁE‹@Ší‚Ì‘I‘ð—\‘ª
@@@@2.1.1 Œ»ÝŠJ”­’†‚Ì‹Zp‚ÌŽÀ—p‰»‚ª”äŠr“Ii“W‚µ‚½ê‡iƒ|ƒWƒeƒBƒuƒP[ƒXj
@@@@2.1.2 Œ»ÝŠJ”­’†‚Ì‹Zp‚ÌŽÀ—p‰»‚ª”äŠr“Ii“W‚µ‚È‚¢ê‡iƒlƒKƒeƒBƒuƒP[ƒXj
@@@2.2 10”NŒã‚ÌŽ¡—ÁE–òÜE‹@Ší‚Ì‘I‘ð—\‘ª
@@@@2.2.1 Œ»ÝŠJ”­’†‚Ì‹Zp‚ÌŽÀ—p‰»‚ª”äŠr“Ii“W‚µ‚½ê‡iƒ|ƒWƒeƒBƒuƒP[ƒXj
@@@@2.2.2 Œ»ÝŠJ”­’†‚Ì‹Zp‚ÌŽÀ—p‰»‚ª”äŠr“Ii“W‚µ‚È‚¢ê‡iƒlƒKƒeƒBƒuƒP[ƒXj@

@m‚Sn‹Ë¶Œú¶‘‡•a‰@‚ł̐f’fEŽ¡—Â̌»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1D“–‰@‚É‚¨‚¯‚é”sŒŒÇ‚̐f’f‚ÆŽ¡—Â̌»ó
@@@1.1 Œ»ó
@@@@1.1.1 ”sŒŒÇ‚Ì”FŽ¯
@@@@1.1.2 ‰Šú‘Ήž
@@@@1.1.3 ‚»‚Ì‘¼‚ÌŒŸ¸
@@@@1.1.4 ‚»‚Ì‘¼‚ÌŽ¡—Ã
@@@1.2 Ž€–S—á‚ÌŒŸ“¢
@@@1.3 ‰Û‘è‚Ɖü‘Pô
@@2D‹ß‚¢«—ˆ‚Ö‚ÌŠú‘Ò
@@@2.1 ˆã—Ñ̐§
@@@2.2 ‹Zp“Ii•à
@@3D‰“‚¢«—ˆ‚Ö‚ÌŠú‘Ò

@m‚Tnº˜a‘åŠw•a‰@‚ł̐f’fEŽ¡—Â̌»ó‚ƍ¡Œã‚̕ω»—\‘ª
@@1DŒ»Ý‚Ì–òÜEŽ¡—Ö@‚Ì‘I‘ð‚ÌŒ»ó
@@@1.1 f’fEŒŸ¸‚ÌŒ»ó
@@@1.2 –òÜ‚Ì‘I‘ðŠî€‚ƃj[ƒY
@@@@@ iR‹Û–òA—AŒŒ—Ö@A‹­SÜAƒXƒeƒƒCƒhAŒŒ‰t»ÜA’Á’É–òA’ÁÃ–ò‚Ȃǁj
@@@1.3 ŒŒ‰tò‰»A“§ÍŽ¡—Â̎ÀŽ{‚â”»’fŠî€‚ɂ‚¢‚Ä
@@2DV–òE‹@ŠíEf’f‹Zp‚ÌŠJ”­‚ªi‚ނƁAŽg‚í‚È‚­‚È‚é‚Å‚ ‚낤»•i‚ƁAV‚½‚ÉŽg—p‹@‰ï‚ª‘‚¦‚»‚¤‚Ȑ»•i
@@@2.1 5”NŒã‚̐f’fEŽ¡—ÁE‹@Ší‚Ì‘I‘ð—\‘ª
@@@2.2 10”NŒã‚̐f’fEŽ¡—ÁE‹@Ší‚Ì‘I‘ð—\‘ª


Ÿ ‘æ‚VÍF”sŒŒÇ—R—ˆ‚ÌŽ¾Š³‚ÌŽ¡—ÂƗLŒø«•]‰¿ @ 

‘æ‚PßF ”sŒŒÇ«DIC‚ÌŽ¡—ÂƗLŒø«•]‰¿
@1DSevere sepsis, Sepsis‚ɑ΂µR‹ÃŒÅ–ò‚ð—p‚¢‚½‘å‹K–Í‹¤“¯‘OŒü‚«Œ¤‹†‚ÌŒ‹‰Ê
@@1.1 The Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Trial
@@1.2 Double-blind, placebo-controlled, multicenter phase 3 clinical trial in patients with severe sepsis (the KyberSept) Trial
@@1.3 The optimized phase 3 tifacogin in multicenter international sepsis trial (OPTIMIST) study
@@1.4 Randomized clinical trial of unfractioned heparin for treatment of sepsis (HETRASE) study
@@1.5 A Randomized, Double-Blind, Placebo-Controlled,Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation
@2DƒKƒCƒhƒ‰ƒCƒ“‚©‚猩‚½”sŒŒÇ«DIC‚ÌŽ¡—Ö@
@@2.1 ‰ÈŠw“Iª‹’‚ÉŠî‚¢‚½Š´õÇ‚É”º‚¤DICŽ¡—ẪGƒLƒXƒp[ƒgƒRƒ“ƒZƒ“ƒTƒX
@@2.2 “ú–{”Å”sŒŒÇf—ÃKƒCƒhƒ‰ƒCƒ“
@@2.3 Surviving Sepsis Campaign (SSC): International Guidelines for Management of Severe Sepsis and Septic Shock
@3D‚Ü‚Æ‚ß

‘æ‚QßF ”sŒŒÇ«”]Ç‚ÌŒ´ˆö‚Æ‚»‚ÌŽ¡—Ö@Šm—§‚̉”\«
@1D”sŒŒÇ«”]áŠQ‚ÌŒ´ˆö
@2D”sŒŒÇ«”]Ç‚ɑ΂·‚鎡—Ö@ŠJ”­‚̉”\«
@3DŽ¡—ÃŒø‰Ê‚Ì”»’è

‘æ‚RßF ×‹Û«‘–Œ‰Š‚ÌŽ¡—ÂƗLŒø«•]‰¿
@1. ×‹Û«‘–Œ‰Š‚ÌŽ¡—Õûj
@@1.1 ”N—î•Ê‚É‚Ý‚½‹Nˆö‹Û‚Ì•p“x
@@1.2 ‹Nˆö‹Û‚Ì–òÜŠ´Žó«
@@1.3 ‹Nˆö‹Û‚̐„’è
@@1.4 ”N—î•Ê‚É‚Ý‚½R‹Û–ò‚Ì‘I‘ð
@@@1.4.1 4‚©ŒŽ`15Î
@@@1.4.2 V¶Ž™`3‚©ŒŽ
@@@1.4.3 16Î`49Î
@@@1.4.4 ‚»‚Ì‘¼
@2. —LŒø«‚Ì•]‰¿‚ƍR‹Û–ò‚Ì“Š—^—Ê‚¨‚æ‚Ñ“Š—^ŠúŠÔ

‘æ‚SßF Š´õ«S“à–Œ‰Š‚ÌŽ¡—ÂƗLŒø«•]‰¿
@1. Ž¡—Ã
@@1.1 Žs’†”­Ç
@@1.2 ‰@“à”­Ç
@@1.3 ŽèpŒã‚ÌŽ¡—ÊúŠÔ
@2. —LŒø«•]‰¿
@3. Š´õ«S“à–Œ‰Š‚̏Ǘá
@@3.1 MSSA‚É‚æ‚éS“à–Œ‰Š
@@3.2 MRSA‚É‚æ‚éS“à–Œ‰Š‚̏Ǘá

‘æ‚TßF ”sŒŒÇ—R—ˆ‚Ì‹}«táŠQ‚ÌŽ¡—ÂƗLŒø«‚Ì•]‰¿
@1DAKI‚Ì’è‹`‚ƉuŠw
@@1.1 AKI‚Ì’è‹`
@@1.2 AKI‚̉uŠw
@2DSeptic AKI‚Ì”­ÇƒƒJƒjƒYƒ€
@@2.1 humoral mediator‚ÌŠÖ—^
@@2.2 septic AKI‚Ì•a‘Ԑ¶—
@@2.3 AKI‚̃oƒCƒIƒ}[ƒJ[
@@@@2.3.1 NGAL(neutrophil gelatinase-associated lipocalin)
@@@@2.3.2 KIN(kidney injury molecule)-1
@@@@2.3.3 L-FABP(L-type fatty acid-binding protein)
@@@@2.3.4 IL(interleukin)-18
@@@@2.3.5 IL-6
@@@@2.3.6 ƒVƒXƒ^ƒ`ƒ“C
@@@@2.3.7 NAG(N-acetly-ƒÀ-D-glucosaminidase)
@3DSeptic AKI‚ÌŽ¡—ÂƗ\–h
@@3.1 septic AKI‚Ì—\–h
@@3.2 septic AKI‚ÌŽ¡—Ã
@@@@3.2.1 —˜”AÜ
@@@@3.2.2 ’á—p—ʃhƒpƒ~ƒ“
@@@@3.2.3 ƒJƒ‹ƒyƒŠƒ`ƒhiƒ¿-hANPj
@@@@3.2.4 ‚»‚Ì‘¼

‘æ‚UßF ”sŒŒÇ«ŠÌáŠQ‚ÌŽ¡—ÂƗLŒø«•]‰¿
@1D•a‘Ô
@2DŽ¡—Ã
@@2.1 Š´õ‘ƒœ‹Ž
@@2.2 “KØ‚ȍR‹Û–ò‚ÆŠeŽí–òÜ‚Ì“Š—^
@@2.3 Œo’°‰h—{ŠÇ—
@@2.4 ‹}«ŒŒ‰tò‰»–@
@@@2.4.1 ƒGƒ“ƒhƒgƒLƒVƒ“‹z’…—Ö@
@@@2.4.2 Ž‘±“IŒŒ‰tàh‰ß“§Í(CHDF;continuous hemodiafiltration)
@@2.5 ŠÌ‘Ÿ•â•—Ö@AŠÌˆÚA
@3D—LŒø«•]‰¿

‘æ‚VßF ”sŒŒÇ«ŠÖß‰Š‚ÌŽ¡—ÂƗLŒø«•]‰¿
@1D”sŒŒÇ«ŠÖß‰Š‚ÌŽ¡—Ã
@@1.1 ŠÖß‰Š‚𐶂¶‚Ä‚¢‚é•”ˆÊ‚Ì“¯’è
@@1.2 R¶•¨Ž¿‚Ì‘I‘ð‚Æ“Š—^
@@1.3 ŠÖß‚ɑ΂·‚éŠO‰È“Iˆ’u
@2D—LŒø«•]‰¿
@@2.1 —Տ°Çó
@@2.2 ŒŸ¸ŠŒ©

‘æ‚WßF ”sŒŒÇ«”xáŠQ‚ÌŽ¡—ÂƗLŒø«•]‰¿
@1. ‹}«”xáŠQ‚Ì’è‹`
@2. ”sŒŒÇ‚É”º‚¤ARDS
@3. ”sŒŒÇ«ARDS‚ÌŽ¡—Ã


Ÿ ‘æ‚WÍF—Տ°Œ»ê‚Ì”sŒŒÇŽ¡—Ẫj[ƒY‚ÆŒ¤‹†ŠJ”­@`Še—̈æ‚Å‹‚ß‚ç‚ê‚é–òÜ/f’f` @ 

‘æ‚PßF Šef—ÉȂɂ¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY‚ÆŒ¤‹†ŠJ”­

@m‚PnzŠÂŠí“à‰È‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1. ”sŒŒÇ‚Ì’è‹`‚ƉuŠw
@@2. zŠÂŠí“à‰È‚É‚¨‚¯‚é”sŒŒÇf—Â̌»ó
@@@2.1 Š´õ«S“à–Œ‰Š
@@@2.2 ŒŒŠÇ“àƒJƒe[ƒeƒ‹Š´õÇ
@@3. ”sŒŒÇf—Âɂ¨‚¯‚é‰Û‘è‚ƃj[ƒY

@m‚QnÁ‰»Ší“à‰È‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1DÁ‰»Ší—̈æ‚É‚¨‚¯‚é”sŒŒÇ‚Ì•p“x‚ÆŒ»ó
@@2D”sŒŒÇ‚ÌŠî‘bŽ¾Š³‚ÆŽ¡—Â̌»ó
@@@2.1 ‹}«’_ŠÇ‰Š
@@@2.2 ŠÌd•ÏŠ³ŽÒ‚É‚¨‚¯‚銴õÇ@“Á‚É“Á”­«×‹Û«• –Œ‰Š
@@@2.3 ‹}«äX‰Š
@@@2.4 ‘±”­«• –Œ‰Š
@@3DŒ»Ý‚̃Aƒ“ƒƒbƒgƒj[ƒY

@m‚RnÁ‰»ŠíŠO‰È‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒhƒj[ƒY
@@1D“ñŽŸ«• –Œ‰Š‚©‚ç‚Ì”sŒŒÇ
@@2D”sŒŒÇ‚̐f’fAŽ¡—ÁAŠÇ—
@@@2.1 f’fAŠ´õŒ¹‚Ì’Tõ
@@@2.2 R‹Û–òŽ¡—Ã
@@@2.3 Š´õŒ¹‚̃Rƒ“ƒgƒ[ƒ‹
@@@2.4 lHŒÄ‹zŠÇ—
@@@2.5 ‰h—{—Ö@
@@3D“ú–{‚ÆŠCŠO‚Ƃ̍·ˆÙ
@@4D¡Œã‚ǂ̂悤‚Ȑ»•i‚ª—~‚µ‚¢‚©EŠú‘Ò‚³‚ê‚é–òÜE‹@Ší“™‚̃vƒƒtƒ@ƒCƒ‹
@@@4.1 —\–hŠú
@@@@4.1.1 “ñŽŸ«• –Œ‰Š‚ÌŒ´ˆöŽ¾Š³‚©‚ç• –Œ‰Š‚Ɉڍs‚³‚¹‚È‚¢‚½‚ß‚Ì–òÜAŒŸ¸–@A‹@Ší‚ÌŠJ”­
@@@@4.1.2 • –Œ‰Š‚©‚ç”sŒŒÇ‚Ɉڍs‚³‚¹‚È‚¢‚½‚ß‚Ì–òÜAŒŸ¸–@A‹@Ší‚ÌŠJ”­
@@@4.2 f’fŠú
@@@@4.2.1 Œ´ˆöŽ¾Š³‚Ì‘ŠúŠm’èf’f‚Ì‚½‚ß‚Ì‹@Ší‚ÌŒŸ¸–@A‹@Ší‚ÌŠJ”­
@@@4.3 Ž¡—Êú
@@@@4.3.1 Š´õÇ‚ÌŽ¡—Â̂½‚ß‚Ì–òÜA‹@Ší‚ÌŠJ”­
@@@@4.3.2 ”sŒŒÇ‚ÌŽ¡—Â̂½‚ß‚Ì–òÜA‹@Ší‚ÌŠJ”­
@@@@4.3.3 p’†‚Ì–òÜA‹@Ší‚ÌŠJ”­
@@@4.4 pŒã‹}«Šú
@@@@4.4.1 pŒãôò
@@@@4.4.2 ‰h—{
@@@@4.4.3 ‘̈ʕϊ·

@m‚Snt‘Ÿ“à‰È‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY`Septic AKI‚𒆐S‚Æ‚µ‚Ä
@@1DSeptic AKI‚Ì’è‹`
@@2DAKI‚Ì•ª—ނɂ‚¢‚Ä
@@3DSeptic AKI‚Ì‘¼‘ŸŠí‚ւ̉e‹¿
@@4DSeptic AKI‚ª¶‚¶‚郁ƒJƒjƒYƒ€
@@5DAKI‚ÌŒŒ´ƒ}[ƒJ[
@@@5.1 ƒNƒŒƒAƒ`ƒjƒ“
@@@5.2 ƒVƒXƒ^ƒ`ƒ“C
@@@5.3 ŒŒ´NGALiNeutrophil gelatinase-associated lipocalinj
@@6DAKI‚ƈâ“`Žq
@@7DAKI‚ÌŽ¡—Ã
@@@7.1 Š´õÇEŠ´õ‘ƒƒRƒ“ƒgƒ[ƒ‹
@@@7.2 ‘̉tŠÇ—
@@@7.3 ŒŒˆ³ŠÇ—
@@@7.4 —˜”A–ò
@@@7.5 Septic AKI‚ɑ΂·‚é‹}«ŒŒ‰tò‰»–@
@@@7.6 PMX-DHP
@@8DAKI‚Ì—\Œã
@@9D¡ŒãŠú‘Ò‚³‚ê‚é–ò•iEÞ—¿

@m‚TnŒÄ‹zŠí‰È‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1. ŒÄ‹zŠí—̈æ‚É‚¨‚¯‚é”sŒŒÇ‚ÌŽ¡—Â̌»ó
@@@1.1 lHŒÄ‹zŠÇ—
@@@1.2 ‘̈Ê
@@@1.3 ƒXƒeƒƒCƒh
@@@1.4 ƒ^ƒ“ƒpƒN•ª‰ðy‘f‘jŠQ–ò
@@@1.5 R‹ÃŒÅ—Ö@iƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Eˆâ“`Žq‘gŠ·‚¦Œ^Šˆ«‰»ƒvƒƒeƒCƒ“Cj
@@@1.6 ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E1
@@@1.7 ƒPƒgƒRƒiƒ][ƒ‹
@@@1.8 N-ƒAƒZƒ`ƒ‹ƒVƒXƒeƒCƒ“
@@@1.9 ‘¼‚̍RŽ_‰»ì—p‚ð‚à‚–òÜ
@@2DŒÄ‹zŠí—̈æ‚É‚¨‚¯‚é”sŒŒÇ‚ÌŽ¡—ÂɕK—v‚Æ‚³‚ê‚é–òÜ
@@3DŒÄ‹zŠí—̈æ‚É‚¨‚¯‚é”sŒŒÇ‚ÌŽ¡—ÂɊú‘Ò‚³‚ê‚é–òÜ
@@@3.1 œ‘ŠÔ—tŒnŠ²×–E
@@@3.2 ƒXƒ^ƒ`ƒ“
@@@3.3 ƒT[ƒtƒ@ƒNƒ^ƒ“ƒg

@m‚UnS‘ŸŒŒŠÇŠO‰È‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1D—Տ°Œ»ê‚Å‚Ì”sŒŒÇ‚Ì”­ÇEœëŠ³EŽ¡—Â̕p“x
@@2DŽ¡—Â̌»ó
@@3DŠCŠO‚ÌŽ¡—Â̓®Œü
@@4DŽ¡—Â̖ž‘«“x
@@5D¡ŒãŠú‘Ò‚³‚ê‚鐻•i‚â–òÜE‹@Ší“™‚̃vƒƒtƒ@ƒCƒ‹

@m‚Vn”å”AŠí‰È‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1. ”A˜H”sŒŒÇ‚Ì’è‹`‚ƉuŠw
@@2. ”A˜H”sŒŒÇ‚̐f’f
@@@2.1 ŒŒ‰tE”AŒŸ¸
@@@@2.1.1 ŒŒ‰tŒŸ¸
@@@@2.1.2 ”A’¾ŸÔ
@@@@2.1.3 ”A”|—{EŒŒ‰t”|—{
@@@2.2 ‰æ‘œf’f
@@@2.3 ”A˜H”sŒŒÇ‚ð‚«‚½‚·‘ã•\“I‚ÈŽ¾Š³
@@@@2.3.1 ‹}«t᱐t‰Š@
@@@@2.3.2 ”^tÇ
@@@@2.3.3 t”^ᇁEtŽüˆÍ”^á‡
@@@@2.3.4 ‹}«‘O—§‘B‰Š
@@@@2.3.5 ˆãŒ´«‚Ì”A˜HŠ´õÇ
@@3. ”A˜H”sŒŒÇ‚ÌŽ¡—Ã
@@@3.1 ‘SgŠÇ—
@@@3.2 ‡•¹Ç‚ÌŽ¡—Ã
@@@@3.2.1 “œ”A•a
@@@@3.2.2 ”dŽí«ŒŒŠÇ“à‹ÃŒÅÇŒóŒQ(DIC: disseminated intravascular coagulation )
@@@@3.2.3 ‹}«ŒÄ‹z‹‡”—ÇŒóŒQ(ARDS: Acute respiratory distress syndrome)
@@@3.3 R‹Û‰»Šw—Ö@
@@@3.4 Š´õ‘ƒ‚ɑ΂·‚鎡—Ã
@@@3.5 ŒŒ‰tò‰»—Ö@

@m‚WnŽ•‰È‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1. Š´õŒ¹‚Æ‚µ‚Ä‚ÌŒûo
@@@1.1 ŒûoŠ´õÇ‚Æ‘SgŽ¾Š³‚Ì‚©‚©‚í‚è
@@@1.2 ŒûoŠ´õÇ‚Æ”sŒŒÇ‚͈ӊO‚É‚àŠÖ˜A‚ª[‚¢H
@@@1.3 Ž•«Š´õÇ‚©‚瑱”­‚µ‚½[èò•”Š´õÇ‚É”sŒŒÇ‚𔺂Á‚½1—á
@@2. ƒI[ƒ‰ƒ‹ƒ}ƒlƒWƒƒ“ƒgiOMj‚Æ‚Í

‘æ‚QßF ‚ª‚ñ—̈æ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY

@m‚PnisäXE’_“¹Šà‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1D—Տ°Œ»ê‚Å‚Ì”sŒŒÇ‚Ì”­ÇEœëŠ³EŽ¡—Â̕p“x
@@2DŽ¡—Â̌»ó
@@3DŽ¡—Â̖ž‘«“x
@@4D¡Œã‚ǂ̂悤‚Ȑ»•i‚ª—~‚µ‚¢‚©
@@5DŠú‘Ò‚³‚ê‚é–òÜE‹@Ší“™‚̃vƒƒtƒ@ƒCƒ‹

@m‚QnÁ‰»Ší‚ª‚ñ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1. Á‰»ŠÇúE
@@@1.1 Á‰»ŠÇúE‚Ì”­¶‹@˜A”­Œ»ŒXŒü
@@@1.2 Á‰»ŠÇúE‚ÌŽ¡—Ïã‚Ì–â‘è“_
@@2. ƒCƒŒƒEƒX
@@@2.1 ƒCƒŒƒEƒX‚Ì”­¶‹@˜A”­Œ»ŒXŒü
@@@2.2 ƒCƒŒƒEƒX‚ÌŽ¡—Ïã‚Ì–â‘è“_
@@3. ˆ««Žîᇂɔº‚¤‹}«’_“¹‰Š
@@@3.1 ˆ««Žîᇂɔº‚¤‹}«’_“¹‰Š‚Ì”­¶‹@˜A”­Œ»ŒXŒü
@@@3.2 ˆ««Žîᇂɔº‚¤‹}«’_“¹‰Š‚ÌŽ¡—Ïã‚Ì–â‘è“_
@@4D”sŒŒÇŽ¡—Âɂ¨‚¯‚é—Տ°Œ»ê‚©‚ç‚Ì–òÜ‚Ö‚Ì—v–]

@m‚Rn”x‚ª‚ñ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1D”xŠàf—Âł̔sŒŒÇ‚Ì”­Ç
@@@1.1 ”xŠà‚É‚æ‚é’¼Ú“I‚ȉe‹¿
@@@1.2 pŒã‚ÌŠ´õÇ
@@@1.3 Šà‰»Šw—Ö@’†‚Ì”sŒŒÇi”­”M«D’†‹…Œ¸­Çj
@@@1.4 I––Šú‚Å‚Ì”sŒŒÇ
@@2D”sŒŒÇ‚ÌŽ¡—Â̌»ó
@@@2.1 ”xŠà‚É‚æ‚é’¼Ú“I‚ȉe‹¿
@@@2.2 Šà‰»Šw—Ö@’†‚Ì”sŒŒÇi”­”M«D’†‹…Œ¸­Çj
@@@2.3 I––Šú‚Å‚Ì”sŒŒÇ
@@3D¡ŒãŠJ”­‚ªŠú‘Ò‚³‚ê‚éƒc[ƒ‹

@m‚Sn—‘‘ƒ‚ª‚ñ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1. ã”琫—‘‘ƒŠà‚ɑ΂·‚é•W€“IŽ¡—Ã
@@@1.1 Žèp—Ö@
@@@1.2 ‰‰ñ‰»Šw—Ö@
@@@1.3 “ñŽŸ‰»Šw—Ö@
@@2. œ‘—}§‚ÌŠÇ—
@@@2.1 —\–h“IR¶Ü“Š—^
@@@2.2 Colony stimulating factoriCSFj“Š—^
@@@2.3 CPT-11‚ÆUGT1A1‘½Œ^
@@3. ”sŒŒÇ‚̐f’fAŠÇ—
@@@3.1 ”­”M«D’†‹…Œ¸­Ç‚ÌŠÇ—
@@@3.2 ”sŒŒÇ‚ÌŽ¡—Ã

@m‚TnŒŒ‰t‚ª‚ñ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1D‚Í‚¶‚ß‚É
@@@1.1 ”sŒŒÇ‚ÌŒ´ˆö‹Û
@@@1.2 ”sŒŒÇ”­Ç‚Ì”wŒi
@@2D”sŒŒÇ‚Ì—\Œã
@@@2.1 —\Œã
@@@2.2 ”sŒŒÇ‚É‚æ‚鎀–S‚̊댯ˆöŽq
@@3D¡Œã‚ÌŠú‘Ò

@m‚Un”]E’†•_ŒoŒn‚ª‚ñ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1D’†•_ŒoŒn‚ª‚ñŠÂ‹«‚Ì“ÁŽê«
@@@1.1 “ªŠWœ“àŠÂ‹«‚Æ“ªŠW“àˆ³˜´i
@@@1.2 ”]‹@”\A_ŒoÇó
@@@1.3 ‘‰t‚Ɛ…“ªÇ
@@@1.4 ”]•‚Žî
@@@1.5 ”]ƒwƒ‹ƒjƒA
@@@1.6 ŒŒ‰t”]ŠÖ–å
@@2D’†•_ŒoŒn‚ª‚ñ‚Ì•ª—Þ‚Æ‚»‚̗Տ°“I“Á’¥
@@@2.1 _ŒoäPŽî
@@@2.2 “]ˆÚ«”]Žîá‡
@@@2.3 Šà«‘–Œ‰Š
@@@2.4 ˆ««ƒŠƒ“ƒpŽî
@@3D’†•_ŒoŒn‚ª‚ñŽ¡—Âɔº‚¤Š´õÇ
@@@3.1 ƒoƒŠƒA[áŠQ
@@@3.2 _Œo‹@”\áŠQ
@@@3.3 œ‘—}§
@@@3.4 –Ɖu”\’ቺ

@m‚Vn“û‚ª‚ñ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1. ‹ÇŠŽ¡—ÂɊ֘A‚·‚é‚à‚Ì
@@2. ‰»Šw—Ö@‚ÉŠÖ˜A‚·‚é‚à‚Ì
@@@2.1 D’†‹…Œ¸­«”­”M‚ÌŠî–{Ž¡—Õûj
@@@2.2 G-CSF‚ÌŽg—p
@@@2.3 ŠO—ˆ‚ł̃}ƒlƒWƒƒ“ƒg

@m‚WnäNã÷Šà‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1DäNã÷‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚é”A˜H«”sŒŒÇ‚ÌŒ´ˆö
@@@1.1 •p“x
@@@1.2 äNã÷‚ª‚ñŽ¡—ÂƔA˜H«”sŒŒÇ
@@2DäNã÷‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚é”A˜H«”sŒŒÇ‚ÌŽ¡—Ð헪
@@@2.1 äNã÷‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚é”A˜H«”sŒŒÇ
@@@2.2 äNã÷‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚é”A˜H«”sŒŒÇ‚𗈂µ‚â‚·‚¢•a‘Ô
@@@2.3 R‹Û–ò‚ɂ‚¢‚Ä

@m‚Xn”畆‚ª‚ñ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1D—Տ°Œ»ê‚Å‚Ì”sŒŒÇ‚Ì”­ÇEœëŠ³EŽ¡—Â̕p“x
@@2DŽ¡—Â̌»ó
@@3DŠCŠO‚ÌŽ¡—Â̓®Œü
@@4DŽ¡—Â̖ž‘«“x
@@5D¡ŒãŠú‘Ò‚³‚ê‚é–òÜE»•i‚ɂ‚¢‚Ä

‘æ‚RßF –ƉuE‰ŠÇ«Ž¾Š³—̈æ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY

@m‚PnŠÖßƒŠƒEƒ}ƒ`‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1DRA‚ÌŽ¾Š³‚Ì“Á’¥‚ÆŠ´õÇ
@@2DRA‚ÉŽg‚í‚ê‚é–òÜ‚Æ‚ÌŠÖ˜A
@@@2.1 ƒXƒeƒƒCƒh‚Æ”sŒŒÇEdÇŠ´õÇ‚ÌŠÖ˜A
@@@2.2 RƒŠƒEƒ}ƒ`–ò‚Æ”sŒŒÇEdÇŠ´õÇ‚ÌŠÖ˜A
@@@2.3 ¶•¨Šw“I»Ü‚Æ”sŒŒÇEdÇŠ´õÇ‚ÌŠÖ˜A
@@@2.4 ¶•¨Šw“I»Ü‚ÆŒ‹Šj‚ÌŠÖ˜A
@@@2.5 ¶•¨Šw“I»Ü‚Æ“ú˜aŒ©Š´õÇ‚ÌŠÖ˜A
@@@2.6 ¶•¨Šw“I»Ü•Ê‚Ì’ˆÓ“_
@@3DRAŠ³ŽÒ‚Ì”sŒŒÇŽ¡—Â̎ÀÛ
@@4DRAŠ³ŽÒ‚̏dÇŠ´õÇ‚Ì—\–h

@m‚Qn•ÏŒ`«ŠÖßÇ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1. ×‹Û«ŠÖß‰Š‚Ì“Á’¥‚ÆŽ¡—Â̌»ó
@@@1.1 ×‹Û«ŠÖß‰Š‚̉uŠw
@@@1.2 ×‹Û«ŠÖß‰Š‚Ì‹Nˆö‹Û‚ÆŠ´õŒo˜H
@@@1.3 Ž¡—Â̌»ó‚Æ–â‘è“_
@@2. ¡ŒãŠJ”­‚ªŠú‘Ò‚³‚ê‚é–òÜC‹ZpC‹@Ší
@@@2.1 R‹Û–ò‚Ì“Á«
@@@2.2 R‹Û–ò‚̋ǏŠ“Š—^–@
@@@2.3 ƒoƒCƒIƒtƒBƒ‹ƒ€‚ɑ΂·‚é‘΍ô

@m‚Rn‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1. ‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒXiSLEj‚Æ‚Í
@@@1.1 ‰uŠw
@@@1.2 ”­Ç‹@˜
@@@1.3 •aˆöA—Uˆö
@@@1.4 —Տ°Çó
@@@1.5 f’f‚ÆŽ¡—Ã
@@@1.6 —\Œã
@@2. SLE‚ÆŠ´õÇ
@@@2.1 Ž€ˆö‚Æ‚µ‚Ä‚ÌŠ´õÇ
@@@2.2 Š´õÇ‚̊댯ˆöŽq
@@@2.3 Š´õÇ‚ÌŠÓ•Ê‚ÆŽ¡—Ã

‘æ‚SßF “œ”A•a—̈æ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY

@m‚Pn1Œ^“œ”A•ai¬Ž™j‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1Df’f‚Æ•ª—Þ
@@2DŽ¡—ÂƊǗ
@@@2.1 “œ”A•a«ƒPƒgƒAƒVƒh[ƒVƒXiDKAj‚ÌŽ¡—Ã
@@@2.2 Šî‘b]’ljÁƒCƒ“ƒXƒŠƒ“iBBT:basal-bolus insulin therapyj—Ö@
@@@2.3 Ž‘±”牺ƒCƒ“ƒXƒŠƒ“’“üiCSIIFcontinuous subcutaneous insulin infusionj—Ö@
@@@2.4 ƒJ[ƒ{ƒJƒEƒ“ƒeƒBƒ“ƒO–@icarbohydorate countingj
@@@2.5 ŒŒ“œ‚̕␳
@@@2.6 ’ጌ“œ
@@3D“œ”A•a‚É‚æ‚銴õÇ‚̜늳ƒŠƒXƒN
@@4D“œ”A•aŽ¡—Âł̊´õÇ‚ÌŽ¡—Âɂ‚¢‚Ä

@m‚Qn2Œ^“œ”A•ai¬lj‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1D2Œ^“œ”A•aŠ³ŽÒ‚É‚¨‚¯‚銴õÇ‚Ì“Á’¥
@@2D”sŒŒÇ‚Ü‚½‚͏dÇŠ´õÇƒŠƒXƒN‚Æ‚µ‚Ä‚Ì“œ”A•a
@@3D“œ”A•a‘«•a•Ï‚Ì—\–h‚ÆŽ¡—ÊǗ
@@4D¡ŒãŠú‘Ò‚³‚ê‚é“œ”A•a‘«dÇŠ´õÇ‚ÌŽ¡—Ã

‘æ‚TßF Š´õÇ—̈æ‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY

@m‚Pn‚bŒ^ŠÌ‰Šf—Âɂ¨‚¯‚é×‹ÛŠ´õÇ‚ƃAƒ“ƒƒbƒgƒj[ƒY
@@1DCŒ^ŠÌ‰Š‚Ì•a‘Ô‚ÆŒo‰ß
@@@1.1 CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX‚ÌŠ´õ‚Æ–«ŠÌ‰ŠAŠÌd•Ï‚ւ̐i“W
@@2DCŒ^–«ŠÌ‰Š‚É‚¨‚¯‚éƒCƒ“ƒ^[ƒtƒFƒƒ“‚ð—p‚¢‚½Ž¡—Âɂ¨‚¢‚Ä
@@3DŠÌd•Ï‚ƍ׋ۊ´õÇ
@@@3.1 ŠÌd•Ï‚Ì•a‘Ԃƍ׋ۂɑ΂·‚銴õÇ”­ÇƒŠƒXƒNó‘Ԃɂ‚¢‚Ä
@@@3.2 “Á”­«×‹Û«• –Œ‰Š
@@@3.3 H“¹Ã–¬áŽ‚ƍ׋ۊ´õ
@@@3.4 ‚»‚Ì‘¼‚ÌŠ´õÇ
@@4DŠÌŠàA‚»‚Ì‘¼‚ÌŽ¡—Âɂ¨‚¢‚Ä

@m‚Qn”x‰Š‚É‚¨‚¯‚é”sŒŒÇŽ¡—ẪAƒ“ƒƒbƒgƒj[ƒY
@@1D”x‰Š
@@@1.1 ”x‰Š‚Æ‚Í
@@@1.2 ‰ä‚ª‘‚Ì”x‰Š‚̉uŠwA•ª—ށAŒ´ˆö”÷¶•¨
@@@1.3 ”x‰Š‚É‚æ‚é”sŒŒÇ‚Ì”­Ç•p“x
@@2DŽ¡—Â̌»ó
@@@2.1 R‹Û–ò—Ö@‚̍l‚¦•û
@@@@2.1.1 Žs’†”x‰Š(CAP:Community-acquired pneumonia)‚ÌŽ¡—Ã
@@@@2.1.2 ‰@“à”x‰Š(Hospital-acquired pneumonia)‚ÌŽ¡—Ã
@@@@2.1.3 ˆã—ÁE‰îŒìŠÖ˜A”x‰Š(NHCAP)‚ÌŽ¡—Ã
@@@2.2 R‹Û–òˆÈŠO‚̕⏕—Ö@
@@@@2.2.1 ƒXƒeƒƒCƒh
@@@@2.2.2 D’†‹…ƒGƒ‰ƒXƒ^[ƒ[‘jŠQ–ò
@@@@2.2.3 –ƉuƒOƒƒuƒŠƒ“
@@@@2.2.4 ƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒƒNƒ`ƒ“‚Æ”x‰Š‹…‹ÛƒƒNƒ`ƒ“
@@3D¡Œã‚Ì”x‰Š—̈æ‚Ì”sŒŒÇŽ¡—Ẫj[ƒY
@@@3.1 ¡Œã‰½‚ª‰ü’ù‚³‚êA’ljÁ‚³‚ê‚é‚ׂ«‚©
@@@3.2 ¡Œã‚Ì•K—v‚Æ‚³‚ê‚鐻•i

‘æ‚UßF ˆÚAˆã—×̈æ‚É‚¨‚¯‚é”sŒŒÇ‚̃Aƒ“ƒƒbƒgƒj[ƒY

@m‚PnŠÌˆÚA‚É‚¨‚¯‚é”sŒŒÇ‚Ì—\–hEŽ¡—Ẫj[ƒY
@@1. ŠÌˆÚA‚ÉŠÖ˜A‚µ‚½”sŒŒÇ‚Ì•a‘ԁE“Á’¥
@@2. ”sŒŒÇ‚̐f’f
@@3. ŠÌˆÚAŒã”sŒŒÇ‚Ì—\–h‚ÆŽ¡—Ã
@@4. “–‰È‚Å‚ÌŽ¡—ЬÑ
@@5. Ç—á’ñŽ¦
@@6. ¡Œã‚Ì“W–]

@m‚QntˆÚA‚É‚¨‚¯‚é”sŒŒÇ‚Ì—\–hEŽ¡—Ẫj[ƒY
@@1DtˆÚAŠ³ŽÒ‚É‚¨‚¯‚銴õÇ‚Ì“Á’¥
@@@1.1 ˆÚAŒã‚ÌŠ´õÇ‚Ì”­ÇŽžŠú
@@@1.2 ŠëŒ¯ˆöŽq
@@@1.3 ”A˜HŠ´õÇ
@@2DtˆÚAŠ³ŽÒ‚ÌŠ´õÇ‚É‚¨‚¯‚éf’fEŽ¡—Ã
@@@2.1 f’f
@@@2.2 Ž¡—Ã
@@3D‚Ü‚Æ‚ß/tˆÚA•ª–ì‚Å‚Ì”sŒŒÇ—\–hEŽ¡—Ẫj[ƒY

@m‚Rnœ‘ˆÚA‚É‚¨‚¯‚é”sŒŒÇ‚Ì—\–hEŽ¡—Ẫj[ƒY
@@1. ˆÚA‘ŠúiD’†‹…‚ª¶’…‚·‚é‚Ü‚Å‚ÌŠúŠÔjiˆÚAŒã30“ú‚܂Łj
@@2. ˆÚA’†ŠúiˆÚAŒã30`100“új
@@3. ˆÚAŒãŠúiˆÚAŒã100“úˆÈ~j
@@4. ×‹ÛŠ´õÇ
@@5. ^‹ÛŠ´õÇ
@@6. ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õÇ
@@7. ‚»‚Ì‘¼‚̃EƒCƒ‹ƒX

@

@”sŒŒÇ@‘Ð

@